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RESUMO
 
	   viii	  
Introdução: Durante décadas, a vitamina D foi estudada sob o prisma da patologia 
óssea. Porém, estudos recentes têm sugerido uma possível associação entre valores 
baixos desta vitamina e aumento de risco de doença cardiovascular. Uma vez que, o 
síndrome metabólico e seus componentes começam frequentemente a ser 
estabelecidos na adolescência, aumentar o conhecimento sobre esta etapa de vida é 
necessário, a fim de identificar as estratégias para prevenir doença e morbilidade na 
vida adulta. 
Objectivo: Este trabalho teve como objetivo avaliar a associação entre a ingestão 
de vitamina D com o síndrome metabólico e seus componentes em adolescentes de 
13 anos. 
Métodos: Foi realizada uma análise transversal de 1.033 adolescentes de 13 anos, 
membros da coorte “Epidemiological Health Investigation of Teenagers in Porto” 
(EPITeen) que nasceram em 1990 e estavam matriculados em escolas públicas e 
privadas da cidade do Porto, durante o ano letivo de 2003/2004. Através de dois 
questionários estruturados (um respondido em casa, o outro pelos adolescentes na 
escola), foram recolhidos dados sociodemográficos, comportamentais e sobre 
história individual e familiar de doença. A ingestão de vitamina D foi avaliada através 
de um questionário de frequência alimentar. Uma equipa de profissionais de saúde 
realizou medições antropométricas, aferiu a pressão arterial e colheu uma amostra 
de sangue em jejum. Os componentes do síndrome metabólico foram definidos de 
acordo com a definição modificada para a idade do “National Cholesterol Education 
Program Adult Treatment Panel III”. A associação entre a ingestão de vitamina D e 
os componentes do síndrome metabólico foi calculada através de modelos de 
regressão logística. 
Resultados: A mediana de ingestão de vitamina D (P25-P75) foi 4,11 (2,88-5,60) 
µg; sendo superior nos adolescentes que reportaram a toma de suplementos 
vitamínicos e inferior nos adolescentes classificados como obesos ou com 
obesidade abdominal. A prevalência de síndrome metabólico foi de 13,2%. Com a 
diminuição da ingestão de vitamina D, o odds ratio (intervalo de confiança de 95%) 
para colesterol HDL baixo aumentou até 1,22 (0,84-1,78) e até 1,78 (1,00-3,17) para 
IMC elevado. 
Conclusões: Apesar da extremamente baixa ingestão de vitamina D, foi observada 
uma relação inversa com o IMC elevado e com colesterol HDL baixo, embora sem 
significado estatístico. Nenhuma tendência foi encontrada para o odds de ter 
síndrome metabólico. 
 
Palavras-chave: vitamina D, síndrome metabólica, adolescentes.
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ABSTRACT

	   ix	  
Introduction: For decades, a great deal of attention towards vitamin D deficiency has 
been justifiably placed on understanding the consequences of its role on bone health. 
However, growing evidence suggests a possible association between low vitamin D 
levels and increased cardiovascular risk. Since the metabolic syndrome and its 
components often begin to be established throughout adolescence, research regarding 
this stage of life is needed, in order to prevent illness and morbidity in adulthood.  
Objective: This research aimed to evaluate the association of vitamin D intake with 
metabolic syndrome and its components in 13-year-old adolescents. 
Methods: We conducted a cross-sectional analysis of 1033 adolescents aged 13-
years-old, members of the Epidemiological Health Investigation of Teenagers in 
Porto (EPITeen), who were born in 1990 and were enrolled at public and private 
schools in Porto, during the 2003/2004 school year. Data on behavioral, social and 
demographic characteristics and individual and family history of disease were 
collected using two standardized questionnaires (one fulfilled at home and the other 
by the adolescents at school). Vitamin D intake was assed by a food frequency 
questionnaire. A team of experienced nurses, nutritionists and physicians performed 
anthropometric assessment, blood pressure measurement and fasting blood sample 
collection. Metabolic syndrome components were defined according to the National 
Cholesterol Education Program Adult Treatment Panel III definition modified for age. 
Logistic regression was performed in order to estimate the association between 
vitamin D intake and metabolic syndrome components.  
Results:  Median (P25-P75) vitamin D intake was 4.11 (2.88-5.60)  µg; it was higher 
among adolescents who reported the use of vitamin supplements and lower in those 
classified as obese or abdominally obese. Metabolic syndrome prevalence was 
13.2%. The adjusted odds ratio (95% confidence interval) increased with the 
decrease of vitamin D intake until 1.22 (0.84-1.78) for low HDL cholesterol and 1.78 
(1.00-3.17) for high BMI. 
Conclusions: Notwithstanding the extremely low vitamin D intake, an inverse 
relation with high BMI and low HDL cholesterol was observed, though without 
statistical significance. No trend was found for metabolic syndrome. 
 
Key words: Vitamin D, metabolic syndrome, adolescents. 
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1. The burden of cardiovascular disease 
 
Of the estimated 57 million global deaths in 2008, 36 million (63%) were due 
to noncommunicable diseases(1). Population growth and increased longevity are 
leading to a rapid increase in the total number of middle-aged and older adults, with 
a corresponding increase in the number of deaths caused by noncommunicable 
diseases. Projections are that the total number of annual noncommunicable disease 
deaths will reach 55 million by 2030, whereas infectious disease deaths are 
projected to decline over the next 20 years(1). 
 Cardiovascular diseases (CVDs), which include diseases of the heart, brain 
vasculature and blood vessels, remain the leading cause of death and disability 
worldwide.(2) Even though a large proportion of CVDs is preventable, they continue to 
rise mainly because preventive measures are inadequate(3). Over the past two 
decades, cardiovascular mortality rates have declined substantially in high-income 
countries due to a combination of prevention and control measures, which provide 
evidence that investment in prevention is the most sustainable solution for the CVD 
epidemic(4, 5). Even so, it is projected that the annual number of deaths due to CVD 
will increase to 25 million in 2030(1).  
 CVDs are also the main cause of death in Europe accounting for 4 million 
deaths each year, with coronary heart disease (CHD) being the single most common 
cause of death in Europe accounting for 1.8 million deaths each year(6). Stroke by 
itself is the second single most common cause of death in Europe accounting for 
almost 1.1 million deaths each year. Just under half of all deaths from CVD in both 
men and women are from CHD, with stroke accounting for nearly a third of deaths in 
women and a quarter of deaths in men(6). 
  In Portugal, CVDs are the main cause of death, increasing from 26.4% in 
1960 to 38.7% in 2000. Portugal has the highest stroke mortality rate in Western 
Europe, and although reducing dramatically over the past two decades, it remains 
higher than that for most European countries. In contrast, coronary heart disease 
mortality is low and similar to Spain and Italy, countries with historically low coronary 
heart disease rates too (6). 
 One of the main underlying pathological processes that leads to heart attacks 
(coronary heart disease) and strokes (cerebrovascular disease) is atherosclerosis.(2) 
The early changes of atherosclerosis develop in childhood and adolescence due to 
the overall effect of a number of risk factors (5, 7-10). 
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 Atherosclerosis involves an inflammatory process affecting medium and 
large-sized blood vessels throughout the cardiovascular system(11, 12). When the 
lining (endothelium) of these blood vessels is exposed to raised levels of low-density 
lipoprotein cholesterol (LDL cholesterol) and certain other substances, such as free 
radicals, the endothelium becomes permeable to lymphocytes and monocytes. 
These cells migrate into the deep layers of the wall of the blood vessel. A series of 
reactions occur, attracting LDL cholesterol particles to the site. These particles are 
engulfed by monocytes, which are then transformed into macrophages (foam cells). 
Smooth muscle cells migrate to the site from deeper layers of the vessel wall (the 
media). Later, a fibrous cap consisting of smooth muscle and collagen is formed. At 
the same time, the macrophages involved in the original reaction begin to die, 
resulting in the formation of a necrotic core covered by the fibrous cap. These lesions 
(atheromatous plaques) enlarge as cells and lipids accumulate in them and the 
plaque begins to bulge into the vessel lumen. As the process continues, there is 
thinning of the fibrous cap accompanied by fissuring of the endothelial surface of the 
plaque, which may rupture. With the rupture of the plaque, lipid fragments and 
cellular debris are released into the vessel lumen. These are exposed to 
thrombogenic agents on the endothelial surface, resulting in the formation of a 
thrombus. If the thrombus is large enough, and a coronary blood vessel or a cerebral 
blood vessel is blocked, this results in a heart attack or stroke(11, 12). This process can 
develop over many years, starting in the childhood and manifesting as heart attacks 
and strokes in people of middle age(2).  
 Unhealthy behaviours, lead to metabolic/physiological changes: raised blood 
pressure (hypertension); overweight/obesity; raised blood sugar (diabetes); and 
raised blood lipids (dyslipidaemia), causing damage to coronary and cerebral blood 
vessels due to the aforementioned atherosclerotic process. 
 These behavioural and metabolic risk factors often coexist in the same 
person and act synergistically to increase the individual’s risk of developing acute 
vascular events such as heart attacks and strokes(2). The clustering of these risk 
factors, which is associated to insulin resistance and co-occur more often than it 
might be expected by chance, is called the Metabolic Syndrome (MetS)(13). Strong 
scientific evidence demonstrates that reducing total cardiovascular risk results in the 
prevention of heart attacks and strokes, being proven its cost-effectiveness(9).  
 Given its role throughout the life course in the promotion and maintenance of 
good health, it is important to highlight the considerable body of evidence regarding 
the nutritional background of CVDs, since food intake is a relevant modifiable 
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determinant, which, indeed, can contribute to a healthy body weight, an appropriate 
lipid profile and a desirable blood pressure(14). 
 
   
1.1. Risk factors begin at early stages 
 
Low birth weight is associated to an increased risk of adult diabetes and CVD. 
There is increasing evidence that exposure to under nutrition in early life increases 
an individual’s vulnerability to these disorders by “programming” permanent 
metabolic changes(15-17). Behavioural risk factors such as tobacco use or dietary 
habits are learned in childhood/adolescence and continue into adulthood. 
Additionally, in many countries, metabolic risk factors such as obesity and 
diabetes are starting to appear at early ages(9). 
 The importance of the early identification of children at risk of developing the 
MetS and subsequently progressing to type 2 diabetes and cardiovascular disease in 
later life is critical(18, 19). From birth and before, circumstances can predispose a child 
to conditions such as obesity or dysglycaemia. The presence of maternal gestational 
diabetes(20), low birth weight(21), infant feeding practices(22), early adiposity 
rebound(23), and genetic factors may all contribute to a child’s future level of risk. 
Likewise, being raised in an “obesogenic” environment can also have a strong 
impact, as can the influence of socioeconomic factors with weight gain often being 
observed as a positive correlate to affluence in developing countries (24).  
 Cluster-tracking studies have shown that multiple cardiovascular risk factors 
persist from childhood into adulthood in 25-60% of cases(25, 26). Changes of 
atherosclerosis within blood vessels can begin in the first decade of life as fatty 
streaks and plaques(9, 27). However, this may be modifiable as shown by Raitakari et 
al., who disclosed that subjects who either developed or lost their risk factor 
clustering over time had significant changes in their adiposity and lifestyle behaviours 
related to nutrition and physical activity(28). 
 Life course epidemiology was built on the premise that various biological and 
social factors throughout life independently, cumulatively and interactively influence 
health and disease in adult life(29). Adverse health outcomes in adulthood can 
frequently be traced back to disadvantaged conditions earlier on. Such conditions 
may accompany birth and the early years of life, but they may also arise from later 
experiences and personal choices. Therefore, it is of utmost importance to adopt 
	  6	  
measures that promote population’s health at an early stage, preventing illness and 
morbidity later in life. 
1.2. Metabolic disorders 
1.2.1. Overweight and Obesity 
 
To achieve optimal health, the median body mass index (BMI), a measure of 
weight relative to height, for adult populations should be in the range of 21–23 kg/m2, 
while the goal for individuals should be to maintain a BMI in the range 18.5–24.9 
kg/m2(9). 
 Nevertheless, obesity is a growing health problem in both developed and 
developing countries. Worldwide, at least 2.8 million people die each year as a result 
of being overweight or obese, and an estimated 35.8 million (2.3%) of global 
disability-adjusted life years (DALYs) are caused by overweight or obesity(30). In 
2008, 34.0% of adults over the age of 20 were overweight with a BMI greater than or 
equal to 25 kg/m2 (33.6% of men and 35.0% of women). Regarding obesity (BMI 
greater than or equal to 30 kg/m2) 9.8% of men and 13.8% of women were obese 
compared to 4.8% for men and 7.9% for women in 1980(30).  
 Prospective epidemiological studies have shown a relationship between 
overweight or obesity and total mortality, aside from cardiovascular morbidity and 
mortality. In fact, risks of coronary heart disease, ischemic stroke and type 2 diabetes 
mellitus increase steadily with an increasing BMI(31). Obesity is strongly related to 
major cardiovascular risk factors such as raised blood pressure, glucose intolerance, 
type 2 diabetes and dyslipidaemia(9, 30).  
 BMI is commonly used to classify obesity among adults and is recommended 
for use with children. Cut-off criteria are based on the Center for Disease Control and 
Prevention’s 2000 BMI-for-age growth charts for the United States(32). Based on 
current recommendations of expert committees, children and adolescents with BMI 
values at or above the 95th percentile of the sex- specific BMI growth charts are 
categorized as obese(33). Regardless of the classification used, overweight has 
become increasingly prevalent in many countries, especially in those economically 
developed, not only in adult population, but also in children and adolescents. 
 Childhood and adolescence are critical periods for the onset of obesity(34, 35). 
Despite being usually considered as an adult problem, it is increasing in children and 
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adolescents worldwide, already showing some of the aforementioned health 
complications that track into adulthood and may lead to major disorders(6, 31). 
 Results from the 2009–2010 United States National Health and Nutritional 
Examination Survey (NHANES), estimated that 16.9% of children and adolescents 
between 2–19 years old are obese. Between 1976–1980 and 2009–2010, the 
prevalence of obesity increased. However, between 1999–2000 and 2009–2010, no 
significant trend was observed in obesity prevalence in girls, although a significant 
increase was seen in boys. Despite the observation that the trend seems to be 
levelling off, it remains worrisome the high prevalence of obesity observed among 
youth(33).  
 Also in Portugal, a recent systematic review verified that in the period 
comprised between 1995 and 2005, the mean BMI and the prevalence of 
overweight/obesity had a marked increase among younger subjects (20-years-old), 
which allow to recognize that a future increase in the overall burden of obesity in the 
younger Portuguese generation can be expected(36). 
1.2.2. Hypertension 
 
Worldwide, high blood pressure is estimated to cause 7.5 million deaths, about 
12.8% of the total of all annual deaths(37). Globally, the overall prevalence of high 
blood pressure in adults aged 25 and over was around 40% in 2008. The number of 
people with uncontrolled hypertension has risen from 600 million in 1980 to nearly 
one billion in 2008(30).  
Brent et al observed the US trends in prevalence, awareness, treatment, and 
control of hypertension between 1988 and 2008 and verified that rates of 
hypertension increased from 23.9% in 1988-1994 to 28.5% in 1999-2000, but did not 
change between 1999-2000 and 2007-2008. They concluded that hypertension 
control improved, with most of the progress toward the Healthy People 2010 goal of 
controlling BP in 50% of all individuals with hypertension occurring between 1999 
and 2008. However, prevalent hypertension is not decreasing toward the national 
goal of 16% and will likely remain high unless adverse trends in population nutrition 
and BMI occur or pharmacological approaches to hypertension prevention are 
adopted(38).  
In Portugal, the estimated prevalence of hypertension is around 40%(39), being 
the most common self-reported chronic disease in the National Health Survey 
conducted in 2005/2006, with a prevalence of 19.8% and with a frequency higher 
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than 80% in the age groups above the 45-54 years(40). These data that is consistent 
with the PAP study (Prevalence, awareness, treatment and control of hypertension in 
Portugal), where it was found that only 45.7% of participants with hypertension were 
diagnosed, of whom 38.9% were treated and among these only 28.8% had values 
below 140/80 mmHg for systolic and / or diastolic. The younger age groups were 
those who had a lower rate of diagnosis and treatment(41). 
 Long-term follow-up studies have shown that blood pressure levels measured 
in childhood and adolescence are positively associated with blood pressure in early 
adulthood, and that there is a clear association between elevated blood pressure 
level in late adolescence or young adulthood and cardiovascular morbidity and 
mortality(42).  
 In a cross-sectional study, Ramos et al. evaluated 2023 Portuguese 
adolescents and observed a prevalence of hypertension of 22.0% and 13.3% for 
prehypertension. The prevalence of hypertension was higher in males (25.4% vs. 
18.8%), but for both genders blood pressure increased with body mass index. (43) 
 Early detection of hypertension and treatment to reduce cardiovascular risk in 
people with hypertension is vital for prevention of stroke and heart attacks. 
Undetected and uncontrolled hypertension increasing the cardiovascular risk is a 
major contributor to stroke worldwide. The stroke and heart attack risk of people with 
high cardiovascular risk and/or raised blood pressure can be reduced through non-
pharmacological (e.g. low salt diet, physical activity) and pharmacological 
measures(30). Multicountry studies have shown large differences in mean population 
blood pressure, associated with variations in adiposity and dietary salt(44).  
 The trend in recent decades for higher blood pressure among children and 
adolescents(45) means that hypertension will remain a major public health concern. 
1.2.3. Impaired glucose 
 
Diabetes is a major risk factor for CVD. In 2008, diabetes was responsible for 
1.3 million deaths globally. The global prevalence of diabetes was estimated to be 
10%(30). Lack of early detection and care for diabetes results in severe complications, 
including heart attacks, strokes, renal failure, amputations and blindness(30).The risk 
of cardiovascular events is from two to three times higher in people with type 1 or 
type 2 diabetes and the risk is disproportionately higher in women(46, 47). 
Both impaired glucose tolerance and impaired fasting glycaemia are risk 
categories for future development of diabetes and CVD(9). Studies indicate that the 
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risk of cardiovascular morbidity and mortality is already significantly increased in 
those with modestly elevated impaired fasting glucose levels, even if they are below 
the cut-off for diabetes(48, 49).  
 Furthermore, abnormal glucose regulation tends to occur together with other 
known cardiovascular risk factors such as central obesity, elevated blood pressure, 
low HDL cholesterol and a high triglyceride level(50, 51).  
 Despite the low prevalence in children and adolescents(52), the increase in 
BMI has also increased the prevalence of this risk factor in this age group. Once they 
are usually considered as being healthy, many of them seek health care infrequently, 
only for acute problems, with the result that they may go years without contact with a 
health care provider.  
1.2.4. Dyslipidaemia 
 
 Raised blood cholesterol increases the risk of heart disease and stroke. 
Globally, one third of ischemic heart disease is attributable to high cholesterol(9). 
Overall, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) 
and 29.7 million DALYS, or 2% of total DALYS globally. In 2008, the prevalence of 
raised total cholesterol among adults, defined as total cholesterol ≥ 6.2 mmol/l (240 
mg/dl), was 9.7% (8.5% for males and 10.7% for females)(30). 
 Lowering raised serum cholesterol reduces the risk of heart disease. For 
example, a 10% reduction in serum cholesterol in 40-year old men has been 
reported to result in a 50% reduction in heart disease within five years; the same 
serum cholesterol reduction for 70-year old men can result in an average 20% 
reduction in heart disease occurrence within five years(30). 
However, it is important to consider that the lipoprotein profile includes: low-
density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) and 
triglycerides, each component having a different role in the development of CVD. 
LDL cholesterol and triglycerides are central for the development of CVD, namely by 
their role on the development of atherosclerosis, contrasting with HDL cholesterol 
that protects against vascular disease (2). Thus, the lipid profile with elevated LDL 
cholesterol and triglycerides, and low HDL cholesterol, conditions an increased risk 
of cardiovascular disease.  
 The PDAY study (Pathobiological determinants of atherosclerosis in youth) 
and the Bogalusa Heart Study were the first studies to document anatomic changes 
and to relate them with dyslipidaemia. In the PDAY study, arteries and tissues from 
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more than 2000 persons 15-34 years of age, whose deaths were attributed to 
accidents, homicides or suicides, were collected and lipids at time of autopsy were 
analysed. They found that the prevalence of increased coverage of the arterial 
intimal surface, with fatty streaks and fibrous plaques, was associated with elevation 
of serum cholesterol levels(53). The Bogalusa investigators followed a total and 
geographically well-defined community in Bogalusa, USA. In the autopsy studies 
done to persons who had died for accidental causes, they also found significant 
association between atherosclerotic lesions and abnormalities of all lipid 
components(54). 
 In a Portuguese study, which aimed at access prevalence of dyslipidaemia and 
to identify associated characteristics in 1388 13-year-old participants, dyslipidaemia 
was highly prevalent, with presence in 24.5% of the adolescents, similar in boys and 
girls, with family history of dyslipidaemia and BMI being the main determinants of 
dyslipidaemia at this age(55). 
 Given that dyslipidaemia is a major contributing factor for atherosclerosis and 
consequently for cardiovascular diseases, and once its process begins in the first 
decades of life(56), the importance of primary prevention in children and adolescents 
must be reinforced.  
1.3. The metabolic syndrome 
 
The metabolic syndrome (MetS) is defined as a complex of interrelated risk 
factors for CVD and diabetes, characterized by a pro-inflammatory and pro-
thrombotic state, which include elevated fasting glucose, raised blood pressure, 
elevated triglyceride levels, low high-density lipoprotein cholesterol levels, and 
obesity (particularly central adiposity)(13).  
 Various diagnostic criteria have been proposed by different organizations 
over the past decade. More recently, these have come from the International 
Diabetes Federation (IDF)(57) and the American Heart Association/National Heart, 
Lung, and Blood Institute (AHA/NHLBI)(58). Their main difference lies in the measure 
for central obesity, with this being a compulsory component in the IDF definition, 
lower than in the AHA/NHLBI criteria, and ethnic specific(59). 
 It has been found that the syndrome has a rising prevalence worldwide, which 
relates largely to increasing obesity and sedentary lifestyles, being estimated that 
one quarter of the world’s population has already MetS(60). Due to the increasing 
rates of adult obesity and its association with insulin resistance and type 2 diabetes, 
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the National Cholesterol Education Program (NCEP) panel stated that the metabolic 
syndrome will soon have a greater impact on premature coronary artery disease than 
does tobacco(61).  
 This condition is appearing with increasing frequency in children and 
adolescents, driven by the growing obesity epidemic in this young population(62). As 
childhood overweight increases, its medical complications are becoming more 
common and more frequently recognized(63). For example, the prevalence of type 2 
diabetes has risen dramatically among adolescents in the past 20 years(64). Studies 
suggest that a substantial percentage of overweight children and adolescents may 
be afflicted with one or more of the components of the MetS(65, 66). Besides, autopsy 
studies have revealed that overweight in adolescence is associated to accelerated 
coronary atherosclerosis, which makes recent trends even more worrying(67). 
 Even though MetS is associated to more than two-fold increase in the risk of 
cardiovascular events, there is a debate whether it adds information to that provided 
by its individual components or it can be regarded as an alternative risk prediction 
tool. In fact, it remains controversial whether the risk associated with metabolic 
syndrome is greater than the sum of the risk resulting from its component features. 
Definition disparity adds to this controversy(68). 
 Despite the disagreement over the terminology and diagnostic criteria related 
to the metabolic syndrome(69), there appears to be a consensus in the medical field 
that the term metabolic syndrome is acceptable to identify individuals at high risk of 
both type 2 diabetes and cardiovascular disease (CVD)(59).  
 This problem seems to be greater in children and adolescents. While one 
definition, although with gender and ethnicity specific cut-off points, is suitable for use 
in the at-risk adult population, transposing a single definition to children and 
adolescents is problematic, given the difficulty to choose the parameters needed for 
its diagnosis and the choice of adequate cut-offs. Moreover, puberty occurs at 
different chronological ages, therefore, for the same age, similar values of these 
factors may mean different disease risk. Blood pressure, lipid levels, and 
anthropometric variables change with age and pubertal development. Puberty 
impacts on fat distribution and is known to cause a decrease both in insulin 
sensitivity, of approximately 30% with a complementary increase in insulin 
secretion(70), and in adiponectin levels(71). Therefore, single cut-off points cannot be 
used to define abnormalities in children. Instead, values above the 90th, 95th, or 97th 
percentile for gender and age are used. 
 The wide variety of cut-off points used has emphasize the need for a single 
consistent set of criteria, which can be easily measurable and used as the basis for 
	  12	  
future work. Recently the IDF has proposed a new definition of the MetS for children 
and adolescents, with central obesity (waist circumference ≥ 90th percentile) being a 
“sine qua non” plus two or more of the following: systolic blood pressure ≥ 130 or 
diastolic blood pressure ≥ 85 mmHg, triglycerides ≥ 150mg/dl, HDL cholesterol ≤ 40 
mg / dl and glucose ≥ 100mg/dl(72). Inspired, in part, by the IDF definition in adults, 
this new definition builds on previous studies investigating the prevalence of MetS in 
children and adolescents, which have used modified adult criteria with varying cut-off 
points(73, 74) (table 1).  
 
Table 1. A range of some published metabolic syndrome definitions in pediatrics. 
 Cook et al. (73) de Ferranti et al. (74) IDF (72) 
 
Three or more of the following: 
Three or more of the 
following: 
Central obesity + ≥ 2 of 4 
criteria 
WC 
≥ 90th percentile (age and sex 
specific, NHANES III) 
≥ 75th percentile ≥ 90th percentile 
Fasting glucose ≥ 110 mg/dL  ≥ 110 mg/dL ≥ 100 mg/dL 
Triglycerides ≥ 110 mg/dL (age specific, 
NCEP) 
≥ 100 mg/dL ≥ 150 mg/dL 
HDL-C ≤ 40 mg/dL (all ages/sexes, 
NCEP) 
≤ 50mg/dL(boys aged 15-19 
years ≤ 45mg/dl)  
< 40mg/dL 
Blood Pressure ≥ 90th percentile (age, sex and 
height specific, NHBPEP) 
≥ 90th percentile Systolic BP ≥ 130 or 
diastolic BP ≥ 85 mmHg 
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2. Vitamin D  
2.1. Overview and Metabolism 
 
 
Vitamin D has been discovered as the fourth vitamin (therefore the 
denomination). Its characterization and synthesis using photochemistry were 
achieved by Windaus in Göttingen, Germany, in 1923, who was awarded thereafter 
with the Nobel Prize in Chemistry(75). Recognition of the complex activities of vitamin 
D on the calcium homeostasis and bone metabolism has been ignited due to its 
association with rickets in children and osteomalacia in adults(76). 
  For a long time, a great deal of attention has been justifiably placed on 
understanding the consequences of vitamin D deficiency on bone health(77-79). 
However, for nearly three decades, studies on vitamin D broadened their horizon, 
knowing now that its functions go far beyond the regulation of bone metabolism(80-83).  
 Vitamin D, also known as calciferol, comprises a group of fat-soluble seco-
sterols. The major forms are vitamin D2 and vitamin D3. Vitamin D2 (ergocalciferol) is 
found in plants as the product of ultraviolet B irradiation of ergosterol. Vitamin D3 
(cholecalciferol) has its origin from 7-dehydrocholesterol and is the product of 
ultraviolet B irradiation of this compound after transiently passing through pre-vitamin 
D3. The vitamin D3 can either be synthesized in the human epidermis or consumed in 
the diet via the intake of animal-based foods. Both vitamin D3 and vitamin D2 are 
synthesized commercially and found in dietary supplements or fortified foods. The D2 
and D3 forms differ only in their side chain structure. The differences do not affect 
metabolism (i.e. activation), and both forms function as pro-hormones (23). In the 
following vitamin D will be referred to both Vitamin D2 and D3.  
 The classical actions of vitamin D, which by itself is inactive, are due to the 
functions of the active metabolite, calcitriol. 25OHD (calcidiol), the precursor of 
calcitriol, is the major circulating form of vitamin D. It circulates bound to a specific 
plasma carrier protein, vitamin D binding protein (DBP), which also transports vitamin 
D and calcitriol(84). 
 Vitamin D is considered biologically inactive until it undergoes two enzymatic 
hydroxylation reactions. The first takes place in the liver, mediated by the 25-
hydroxylase (most likely cytochrome P450 2R1 [CYP2R1]), which forms 25-
hydroxyvitamin D (25OHD). The second reaction takes place in the kidney, mediated 
by 1α-hydroxylase (CYP27B1), which converts 25OHD to the biologically active 
hormone, calcitriol (1,25-dihydroxyvitamin D). The 1α-hydroxylase gene is also 
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expressed in several extra-renal tissues, but its contribution to calcitriol formation in 
these tissues is unknown (table 2).  
 Two counter-acting hormones tightly regulate the renal synthesis of calcitriol, 
with up-regulation via parathyroid hormone (PTH) and down-regulation via fibroblast-
like growth factor-23 (FGF23). Low serum phosphorus levels stimulate calcitriol 
synthesis, whereas high serum phosphorus levels inhibit it. Following its synthesis in 
the kidney, calcitriol binds to DBP in order to be transported to target organs. The 
biological actions of calcitriol, involve regulation of gene expression at the 
transcriptional level, and are mediated through binding to a vitamin D receptor 
(VDR), located primarily in the nuclei of target cells. Additional hydroxylation 
reactions, such as that mediated by CYP24A1, result in more polar metabolites with 
very limited or no apparent biological activity(85).The actions of calcitriol include the 
regulation of serum calcium and phosphate homeostasis and, in turn, the 
development and maintenance of bone health(85). 
 Non-classical functions are less well elucidated. After 1,25(OH)D enters the 
cell, it is transported through the micro-tubular network to the nucleus. After it enters 
the nucleus bound to its vitamin D receptor (VDR), it complexes with the retinoic acid 
X receptor to form a heterodimeric complex that seeks out specific DNA sequences 
known as vitamin D-responsive elements (VDREs). Once the 1,25(OH)2D3-VDR-
retinoic acid X receptor complex binds to the VDRE, resulting in expression of the 
vitamin D-responsive gene(86). VDRs are found fairly ubiquitously throughout the 
body in tissues not involved with calcium and phosphate homeostasis, and the 
presence of VDRs in these tissues implies that calcitriol may play a more general 
role or that ligands other than calcitriol can activate the VDR(84). Furthermore, 
VDREs, considered the hallmark of vitamin D action, are present in a large number 
of human genes involved in a wide range of classical and non-classical roles, such 
as the regulation of cell proliferation, cell differentiation, and apoptosis. It has been 
suggested that calcitriol exerts immunomodulatory and anti-proliferative effects 
through autocrine and paracrine pathways. These wide-ranging actions of calcitriol 
have further been hypothesized to play a potential role in preventive or therapeutic 
action in cancer and chronic conditions such as autoimmune conditions, infections 
and cardiovascular disease(87-89). 
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Table 2. Terms used in reference to Vitamin D(90). 
 
 
 
 
 
 
 
 
 
 
 
 
Due to its fat-soluble nature, dietary vitamin D (either D2 or D3) is incorporated 
into micelles with other lipids and absorbed into the intestine by passive diffusion. 
The efficient absorption of vitamin D is dependent upon the presence of fat in the 
lumen, which triggers the release of bile acids and pancreatic lipase. In turn, bile 
acids initiate the emulsification of lipids, pancreatic lipase hydrolyzes the triglycerides 
into monoglycerides and free fatty acids, and bile acids support the formation of lipid-
containing micelles, which diffuse into enterocytes. Inside the absorptive cells, the 
vitamin is incorporated into chylomicrons, and enters the lymphatic system and finally 
the plasma, where it is delivered to the liver by chylomicron remnants or to specific 
carrier vitamin D-binding (DBP), or transcalciferin. The efficiency of this absorption 
process is approximately 50%. Vitamin D synthesized in the skin from cholesterol 
enters the capillary system and is transported by DBP and delivered to the peripheral 
tissues. Little Vitamin D is stored in the liver(91, 92). 
 Regardless of its origin, vitamin D is an inactive pro-hormone and must first 
be metabolized to its hormonal form before it can function. Once vitamin D enters the 
circulation from the skin or from the lymph, it is cleared by the liver or storage tissues 
within a few hours(93). 
 Vitamin D is converted in the liver to 25-hydroxyvitamin D [25(OH)D], the 
major circulating metabolite of vitamin D(85). At this point, 25OHD bound to DBP 
circulates in the blood stream and, when calcitriol is required due to a lack of calcium 
(or lack of phosphate), 25OHD is 1α-hydroxylated in the kidney to form calcitriol, the 
active form, by the 1α-hydroxylase enzyme. This metabolic step is very tightly 
Terms: 
Vitamin D—also referred to as calciferol 
Vitamin D2—also referred to as ergocalciferol 
Vitamin D3—also referred to as cholecalciferol 
25OHD—25-hydroxyvitamin D also referred to as calcidiol or calcifediol; 
indicates no distinction between D2 and D3 forms.  
Calcitriol—1,25-dihydroxyvitamin D3 (Note: Ercalcitriol - refers to 1,25-
dihydroxyvitamin D2, but in this report, the term “calcitriol” will be used for 
both) 
24,25(OH)2D—24,25-dihydroxyvitamin D 
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regulated by blood calcium and phosphate levels through PTH and the phosphaturic 
hormone, FGF23, and constitutes the basis of the vitamin D endocrine system that is 
central to maintaining calcium and phosphate homeostasis(85). FGF23 acts by 
reducing the expression of renal sodium–phosphate transporters and reducing serum 
calcitriol levels. All naturally occurring vitamin D compounds interact with DBP. 
Calcitriol and vitamin D have significantly lower affinity for this protein than does 
25OHD. Whereas vitamin D has an average lifetime in the body of approximately 2 
months, 25OHD has a lifetime of 15 days, and calcitriol has a lifetime measured in 
hours(94). Because of this relative stability, the principal biomarker used to assess 
vitamin D status is plasma 25-hydroxyvitamin D concentration. Aside from these key 
elements in vitamin D metabolism, more than 30 other metabolites have been found, 
but their importance seems minimal(94). 
  Adipose tissue stores of vitamin D probably represent “non-specific” stores 
sequestered because of the hydrophobic nature of vitamin D, but the extent to which 
the processes of accumulation or mobilization are regulated by normal physiological 
mechanisms remains unknown. Since vitamin D is stored in body fat and unavailable 
for use, body fat content is considered a factor that decreases its bioavailability. 
Studies show that body mass index and body fat content have an inverse relation to 
serum levels of 25 hydroxyvitamin D(95, 96).  
 The products of vitamin D metabolism are excreted through the bile into the 
feces, and very little is eliminated through the urine. This is in part due to renal 
reuptake of vitamin D metabolites bound to DBP, as mediated by the cubilin–megalin 
receptor system(97). 
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Figure 1. A The final common pathways of generation of 25 (OH)D and 1,25(OH) 2D, the feedback loop, and the 
roles of skin, liver, and the kidney. Eighty percent of the vitamin D requirements of humans is generated through UVB 
rays after skin exposure to sunlight. B Illustrate the physiologic role of PTH in the maintenance of serum calcium 
level. Key target organs for PTH; bone, kidney and intestine, and their feedback interactions with calcium are 
illustrated. C Feedback hormonal control of calcium metabolism. Low serum ionized calcium enhances the secretion 
of PTH from parathyroid glands. Subsequently, PTH increases the synthesis of 1,25(OH)2D, stimulates calcium 
absorption from the intestine, and mobilizes calcium from the skeleton to maintain normocalcemia, and negatively 
regulates PTH synthesis and release. FGF-23= fibroblast growth factor-23; PTH= parathyroid hormone; UVB= 
ultraviolet B. Adapted from Curr Osteoporos Rep, 2012(82).  
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2.2. Sources  
 
Vitamin D is a particular micronutrient, since it can be obtain not only form 
food consumption, but also by skin synthesis throughout UVB rays, which, in fact, are 
its main source, contributing with 80% compared with 20% that come from food(76). 
 Determining adequate levels for vitamin D is rather complex. In fact, vitamin 
D is known as the “sunshine vitamin” because modest exposure to sunlight should 
be sufficient for most people produce their own vitamin D using ultraviolet light and 
cholesterol in the skin. 
 Vitamin D3 is synthesized in human skin from 7-dehydrocholesterol following 
exposure to ultraviolet B (UVB) radiation with wavelength 290 to 320 nm. Its 
production in skin is a function of the amount of UVB radiation reaching the dermis 
as well as the availability of 7-dehydrocholesterol. As such, the level of synthesis 
varies greatly from person to person and is influenced by a number of factors, which 
include season of the year, skin pigmentation, latitude, use of sunscreen, clothing, 
and amount of skin exposed. Even though brief and casual exposer of the face, 
arms, and hands to sunlight could contribute to the decreasing lack of vitamin D, 
people are justifiably advised against sun exposure to reduce the risk of skin 
cancer(98). Age is also a factor, as synthesis of vitamin D declines with increasing 
age, due in part to a fall in 7-dehydrocholesterol levels and also to alterations in skin 
morphology(99). 
 Contrary to excessive oral vitamin D intake, toxic levels of vitamin D do not 
occur from prolonged sun exposure. In fact, thermal activation of previtamin D3 in the 
skin gives rise to multiple non–vitamin D forms, such as lumisterol, tachysterol and 
others, which limit the formation of Vitamin D3 itself. Besides, vitamin D3 can also be 
converted to nonactive forms(100, 101). 
 Vitamin D serum levels are determined by the measurement of 25-
hydroxyvitamin-D, which reflects vitamin D input from both skin absorption of sun and 
dietary intake. Normative values are subject to debate, but most experts use the 
following guidelines: levels less than 20 ng/ml is defined as deficiency; 21 to 29 ng/ml 
is relative insufficiency; 30 ng or greater is sufficient; greater than 150 ng/ml is 
intoxication(76). 
 Dietary sources of vitamin D include food and supplements. There are a few 
naturally occurring food sources of vitamin D, which include fatty fish, fish liver oil, 
and egg yolk. Some foods are, however, fortified with vitamin D, such as fortified 
milk, margarine and cereal(102) (table 3). In recent years, dietary supplements 
containing vitamin D have become more common and have been more frequently 
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consumed. The form of vitamin D used in supplement products can be either vitamin 
D2 or vitamin D3(82). 
 
Table 3. Major food sources of vitamin D. 
Selected food sources International Units (IU) per serving 
Cod liver oil (1 tablespoon) 1360  
Swordfish, cooked (3 ounces) 566 
Salmon, cooked (3 ounces) 447  
Tuna fish, canned in water (3 ounces) 154  
Egg yolk (one) 40 
Adapted from The National Institutes of Health, June 2011 
 http://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ 
 
 Vitamin D levels in the diet are expressed in International Units (IU), but can 
also be expressed in micrograms (µg). The biological activity of 1 µg of vitamin D is 
equivalent to 40 IU (table 4). 
 
Table 4. Conversions used in reference to Vitamin D(90). 
 
 
 
 
 
 
 
 
 Although some aspects of vitamin D nutrition and physiology have been 
found to differ with life stage, most of the functions of vitamin D are quite consistent 
across life stages from infancy and childhood, to adolescence, adulthood, and old 
age(90). Therefore, the recommendations from the Institute of Medicine (IOM) 2011, 
which assumed minimal sun exposure when establishing the DRIs for vitamin D, 
determined that 600 IUs of vitamin D per day meets the needs of almost everyone, 
except people aged 71 and older, who may need as much as 800 IUs per day due to 
potential changes in people’s bodies as they age(90). 
 The Estimated Average Requirements (EARs), Recommended Dietary 
Allowances (RDAs), and Adequate Intakes (AIs) for vitamin D by life stage group are 
shown in table 5. The identical EARs across age groups are notable, reflecting the 
concordance of serum 25OHD levels with the integrated bone health outcomes as 
well as the lack of an age effect on the simulated dose-response(90). 
IU = International Unit is a measurement based on biological activity or 
effect; 1 IU of vitamin D is defined as the activity of 0.025 µg of 
cholecalciferol in bioassays with rats and chicks. 
Conversions for Vitamin D3: 
[sources] 40 IU = 1 µg 
[serum] 2.5 nmol/L = 1 ng/mL 
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 For very young children in this life stage group, no data is available to link 
vitamin D directly to measures related to bone health outcomes(90). Regarding 
adolescence ensuring normal, healthy bone accrual is central to the DRI values. The 
requirement distribution developed using serum 25OHD concentrations and the 
intakes estimated to achieve such concentrations are the basis for the reference 
values(90). Thus, IOM indicates that an intake of vitamin D of 400 IU/day achieves 
serum concentrations of 40 nmol/L, and this intake is therefore set as the EAR for 
persons 1 to 3 years, 4 to 8 years, 9 to 13 years, and 14 to 18 years of age. As this 
requirement distribution appears to be normally distributed, the assumption of 
another 30 percent to cover nearly all the population (i.e., 97.5 percent) is 
appropriate and consistent with a serum 25OHD level of approximately 50 nmol/L as 
the target for an RDA value. Based on the same analysis relating serum 25OHD 
levels to intake, an intake of 600 IU/day is set as the RDA(90) . 
  
Table 5. Vitamin D Dietary Reference Intakes (DRIs) for Adequacy (amount/day).  
 
AI = Adequate Intake; EAR = Estimated Average Requirement; IU = International Unit;  
RDA = Recommended Dietary Allowance.  
Adapted from The Institute of Medicine 2011.  
Life Stage Group AI EAR RDA 
Infants    
0 to 6 mo 400 IU (10mcg) - - 
6 to 12 mo 400 IU (10mcg) - - 
Children    
1-3 y - 400 IU (10mcg) 600 IU (15mcg) 
4-8 y - 400 IU (10mcg) 600 IU (15mcg) 
Adolescents (both 
genders) 
-   
9-13 y - 400 IU (10mcg) 600 IU (15mcg) 
14-18 y  400 IU (10mcg) 600 IU (15mcg) 
Adults  
(both genders) 
   
19-30 y - 400 IU (10mcg) 600 IU (15mcg) 
31-50 y - 400 IU (10mcg) 600 IU (15mcg) 
51-70 y - 400 IU (10mcg) 600 IU (15mcg) 
> 70 y - 400 IU (10mcg) 800 IU (20mcg) 
Pregnancy    
14-18 y - 400 IU (10mcg) 600 IU (15mcg) 
19-30 y - 400 IU (10mcg) 600 IU (15mcg) 
31-50 y - 400 IU (10mcg) 600 IU (15mcg) 
Lactation -   
14-18 y - 400 IU (10mcg) 600 IU (15mcg) 
19-30 y - 400 IU (10mcg) 600 IU (15mcg) 
31-50 y - 400 IU (10mcg) 600 IU (15mcg) 
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In recent years numerous position statements and clinical practice guidelines 
have been published to define the optimal vitamin D status and the health outcomes 
associated with its alteration(103, 104). Different recommendations on dietary intakes 
needed to reach and maintain sufficient 25(OH)D levels have been proposed as 
well(90, 105-108). In this context, the publication of the most authoritative report on these 
issues for the general population, The Institute of Medicine concluded that 25(OH)D 
levels above 20ng/ml are needed for good bone health for almost individuals (97,5% 
of the population), while a level of 16ng/ml (40nmol/l) meets the need of 
approximately half the population(90). According to IOM, higher levels of 25(OH)D 
have not been consistently shown to confer greater benefits, in turn challenging the 
concept that “more is better”. It highlights the need to take into account several 
factors when interpreting the results of current literature, which include the difficulty 
to distinguish the sole effect of vitamin D as the majority of intervention trials co-
administered calcium; the difficulty to exactly measure the relative contribution of 
sunlight exposure, foods fortification and multivitamins intake; the lack of randomized 
trials assessing the effect of vitamin D supplementation on health outcomes other 
than bone and the complexity to compare studies utilizing different 25(OH)D 
assays(109-112).  
 In fact, the primary health outcomes of vitamin D intake utilized to define 
vitamin D sufficiency are those related to skeletal health. Concerning the other 
possible benefits of vitamin D, IOM concluded that existing data is not sufficient to 
support the recommendation of vitamin D supplementation to reduce the risk of 
extra-skeletal acute and/or chronic diseases(90). 
 The definition of vitamin D deficiency, insufficiency and sufficiency is currently 
challenging as an overall consensus is still lacking(82, 113, 114). It represents a crucial 
issue, since the identification of different thresholds defining vitamin D status has 
varying implications in clinical practice. First, the worldwide prevalence of low vitamin 
D status is highly varying according to the level of 25(OH)D utilized to define 
sufficiency. Consequently, the choice to initiate vitamin D supplementation may 
change, as well as the goals of therapy, the dosing strategy, and the decision about 
who should be screened, if necessary, and how often(115). 
 In general, for every 100 IU (2,5µg) of vitamin D taken in, 25(OH)D levels 
increase of about 1ng/ml, but with a huge inter-individual variability.  Several factors 
may account for such variability: the initial 25(OH)D concentration, patient’s weigh, 
adequacy of dose according to compliance, the type of vitamin administered (D2 or 
D3), renal function, and genetic factors. The variability in absorption, the inaccuracy 
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of 25(OH)D assessment, as well as unknown factors also probably contribute to the 
variability of the dose-response relationship(116-118). 
 Controversy also exists on whether supplementation should be given daily or 
intermittently (e.g. weekly, monthly, once a year). It has been shown that circulating 
levels of 25(OH)D increase similarly when oral vitamin D is given daily, weekly or 
monthly, proving that the total amount is identical. However, it must be recognized 
that a universal guideline does not exist, most likely the result of great disparity 
among countries in the availability of vitamin D supplements(119). 
 The immediate aim of treatment should be quick normalization of 25(OH)D 
levels, as well as vitamin D stores, which can be accomplished with an initial period 
of high-dose vitamin D. An intermittent high-dose therapy is an interesting option to 
avoid non-adherence to treatment, although a regimen of regular low-dose is a 
reasonable alternative(120). Studies comparing the two different regimens reported 
inconsistent results, and both high-dose (dosing interval < 2 months) and more 
regular low-dose seem to offer similar efficacy(121-123). The maximum safe bolus 
remains uncertain. A number of papers reported that a single oral dose of 300,000-
600,000IU of D2 or D3 rapidly enhances serum 25(OH)D and reduces PTH levels in 
patients with deficiency(124, 125). However, the study by Sanders and co-workers 
showing that 500,000IU oral dose of cholecalciferol increased the risk of falls and 
fractures among older women deserves attention(126). Another trial reported that 
300,000 IU of ergocalciferol given intramuscularly for 3 years to elderly people during 
fall season did increase fracture risk(127). No plausible biological explanation has 
been given for these results, whose interpretation remains merely speculative. 
However, these papers raise the possibility that infrequent high doses of vitamin D 
status may be unsafe, counteracting any possible beneficial outcome. The rate and 
magnitude of the increase in serum 25(OH)D levels may be critical, as well as at 
which time points 25(OH)D concentration should be measured after dosing. On the 
other hand, it is undeniable that, on a population basis, the utilisation of intermittent 
doses could aim to overcome the problem of compliance(128-130). 
 Once vitamin D stores are replete, a maintenance dose of 800 to 2000IU (20 
to 50 µg) should be recommended. In particular, long-term supplementation has to 
be encouraged in special groups that are at high risk of deficiency. At this regard, 
many experts have questioned the IOM recommendations since, in the absence of 
sun exposure and dietary input, a daily dose of 600 IU (15 µg) of vitamin D will not 
maintain blood 25(OH)D levels, even at 20ng/ml(131, 132). Hence, higher doses may be 
probably necessary to achieve an optimal vitamin D status. 
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 Regarding the type of vitamin D supplementation, current evidence suggests 
that ergocalciferol has a considerably lower efficacy than cholecalciferol in raising 
circulating 25(OH)D level(120). This difference between the two calciferols relates to 
several factors: the different affinity for the vitamin D binding protein and VDR, the 
different calciferols relates to several factors: the different affinity for the vitamin D 
binding protein and VDR, the different affinity as substrate for hepatic 25-hydroxilase, 
a possible difference in the 24-hydroxilation rate. In fact, the metabolism of vitamin D 
involves 24-hydroxilation in the kidney to form 1,24,25(OH)3D. This step is critical, 
since once 1,24,25(OH)D3D2 has been formed, ergocalciferol has been deactivated 
and, therefore, is irretrievable. On the contrary, the 1,24,25(OH)3D3 still binds to VDR 
[≈ 40% more than 1,25(OH)D2D3] and must undergo additional side chain oxidation 
to be biologically deactivated. This additional step gives a vast advantage and 
potential for cholecalciferol to remain biologically active and, thus, maintain vitamin D 
status. Available data also document the higher efficacy of cholecalciferol, regardless 
the frequency of administration (small doses or in larger and more infrequent 
bolus)(133-135).  
 When considering the route of administration, both cholecalciferol and 
ergocalciferol are available as oral or intramuscular (IM) preparations. In general, 
oral administration is more physiological and leads to a rapid increase in serum 
25(OH)D levels within 3 days(124). With IM injection a gradual increase in serum 
25(OH)D levels was observed, thus demonstrating delayed serum 25(OH)D 
response(124). This phenomenon is probably due to the sequestration of vitamin D in 
the muscle and fat, where it is gradually released. It has been hypothesized that this 
pharmacokinetic profile potentially allows IM preparations to overcome the fluctuation 
of serum 25(OH)D levels following high oral bolus(136). However, this point has not 
been definitively clarified. On the other hand, intramuscular preparations may have 
specific indications, in particular for intermittent (once or twice-yearly) high-dose 
regimens(137). 
 As aforementioned, vitamin D intoxication is rather unusual. In fact, the 
potential harm of vitamin D may only come from the excessive ingestion of 
supplements, as after intensive solar UVB irradiation the skin synthesis of vitamin D 
is self-regulated as inactive metabolites are produced, available data demonstrating 
that skin synthesis of up to 10,000IU (250 µg) daily is safe. Moreover, the 
contribution of dietary sources is usually about 10-20% being intoxication from this 
source nearly impossible(138, 139). The condition of hypervitaminoses D leads to 
hypercalcemia and eventually to soft tissue calcification and resultant renal and 
cardiovascular damage(85). 
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 A number of studies linked the amount of vitamin D intake to the achieved 
25(OH)D serum levels, in order to establish a threshold for intoxication. It has been 
reported that an intake of 10,000IU/d (250g/d) of vitamin D is not harmful, which 
correspond to a 25(OH)D serum level of about 88ng/ml (220nmol/l)(140). 
Nevertheless, the IOM recently set the upper safe level of 25(OH)D at about 50ng/ml 
(125nmol/l), on the basis of observational studies showing an U-shaped association 
between circulating 25(OH)D and some clinical outcomes (frailty, all cause mortality, 
cancer, falls and fractures)(141). 25(OH)D serum levels beyond this limit are 
considered potentially harmful. However, this threshold seems to be very 
conservative, especially if we take into consideration many published studies 
showing that doses around 4000IU/d (100 µg/d) of vitamin D are safe, even in the 
long-term treatment. The 25(OH)D serum level achieved in these studies was 
between 30 and 64ng/ml (75 and 160 nmol/l), and it was not accompanied by any 
clinical sign of intoxication(139). 
2.3. Functions an physiological actions  
 
Vitamin D has both genomic and nongenomic functions. For the genomic 
functions, 1,25(OH)2D interacts with nuclear vitamin D receptors to influence gene 
transcription(86). Nuclear receptors for 1,25(OH)2D have been identified in over 30 
cell types, including bone, intestine, kidney, lung, muscle and skin. For the 
nongenomic functions, 1,25(OH)2D acts like a steroid hormone, working through 
activation of signal transduction pathways linked to vitamin D receptors on cell 
membranes. Major sites of action include intestine, bone, parathyroid, liver and 
pancreatic beta cells. Biological actions include increases in intestinal calcium 
absorption, transcellular calcium flux and opening gated calcium channels allowing 
calcium uptake into cells such as osteoblasts and skeletal muscle(86). 
 The dominant function of vitamin D in its hormonal form (calcitriol or 1,25-
dihydroxyvitamin D) is the elevation of plasma calcium and phosphate levels, which 
are required for mineralization of bone(142). Furthermore, the elevation of plasma 
calcium to normal levels is also required for the functioning of the neuromuscular 
junction as well as vasodilatation, nerve transmission, and hormonal secretion(143).  
 Calcitriol, functioning as part of the endocrine system for maintaining serum 
calcium levels, elevates plasma ionized calcium levels to the normal range by three 
different mechanisms.         
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 The first mechanism is the well-established role of calcitriol in stimulating 
intestinal calcium absorption throughout the entire length of the intestine, although its 
greatest activity is in the duodenum and jejunum. It is clear that calcitriol directly 
stimulates intestinal calcium and, independently, phosphate absorption. In the 
second mechanism, calcitriol plays an essential role in the mobilization of calcium 
from bone, a process requiring PTH. It induces the formation and activation of the 
osteoclast to function in the mobilization of calcium from bone. In short, calcitriol 
facilitates the formation of osteoclasts by stimulating the secretion of a protein called 
receptor activator for nuclear factor κ B (RANK) ligand, which, in turn, is responsible 
for osteoclastogenesis and bone resorption. In the third mechanism, calcitriol 
together with PTH stimulates the renal distal tubule reabsorption of calcium, ensuring 
retention of calcium by the kidney when calcium is needed(144, 145). 
    Therefore, overall, calcitriol acts on the intestine, bone, and kidney as 
described above, to elevate serum calcium levels, closing the calcium loop(146). As 
serum calcium levels rise, PTH secretion drops. If serum calcium levels become too 
high, the parafollicular cells (“C” cells) of the thyroid secrete calcitonin, which blocks 
calcium resorption from bone and helps to keep calcium levels in the normal range. 
Calcitriol, through its receptor, the VDR, suppresses parathyroid gene expression 
and parathyroid cell proliferation, providing important feedback loops that reinforce 
the direct action of increased serum calcium levels(146). 
    In addition to the aforementioned mechanisms, it was recently recognized 
that the VDR is present in the nucleus of many tissues that are not involved in the 
regulation of calcium and phosphate metabolism(147). The role of this paracrine 
production of 1,25(OH)D in these tissues is not well understood, but a variety of in 
vitro studies indicated that this process may be involved in a wide range of 
physiologic functions, including regulation of cytokines, inflammatory and/or fibrotic 
pathways, the renin-angiotensin system, vascular and cardiac cell function, immune 
response modulation, cell growth and differentiation, and others(88, 148, 149). For 
example, the VDR has been clearly described in epidermal keratinocytes, in 
activated T cells of the immune system, in antigen-presenting cells, in macrophages 
and monocytes, and in cytotoxic T cells(150). Gene array studies in many cells and 
tissues show that calcitriol regulates several hundred genes throughout the body or 
as much as 5 percent of the human genome, though exactly how calcitriol functions 
in these tissues and the physiological consequences are not clearly known(151). 
    Several of the biologic pathways through which the effects of 1,25(OH)D are 
mediated remain poorly understood but may account for its role in cardiovascular 
health.  
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3. Vitamin D and the metabolic syndrome 
 
Low vitamin D status is being increasingly recognized as widespread in all life 
stages, even in sunny climates(81, 152).  
 Beside its role in bone metabolism, the possible importance of vitamin D 
deficiency as a novel risk factor for various chronic diseases has gained more 
interest. One area of recent study has been the investigation of the association 
between vitamin D status and the metabolic syndrome(89, 153). 
 Although the underlying biological causes are not fully understood, the 
association of 25OHD with cardiovascular pathology is suggested to be driven by 
various mechanisms: apart from a potential direct impact on cardiomyocytes and 
myocardial diseases(83) it has been suggested that 25OHD indirectly modifies CVD 
risk(154) by its association with cardiovascular risk factors like diabetes(155), 
hypertension(156), or cholesterol level(157). 
     Epidemiological studies have suggested that low vitamin D status is 
associated to the development of the metabolic syndrome. Ford et al. reported the 
association in the NHANES III, a nationally representative cross-sectional survey of 
the noninstitutionalized population in the United States carried out during 1988–1994, 
between vitamin D status and the metabolic syndrome in 8421 men and nonpregnant 
women who were 20 years of age or older. The mean serum 25-hydroxyvitamin D 
concentration in those with metabolic syndrome was significantly lower (67.1 nmol/L) 
than that in subjects without metabolic syndrome, which in turn had a mean serum 
25-hydroxyvitamin D concentration of 75.9 nmol/L. When compared by quintiles of 
serum 25-hydroxyvitamin D, they also found a significant inverse association with the 
metabolic syndrome and some of the individual components (abdominal adiposity, 
hypertriglyceridemia, and hyperglycaemia)(158). 
  In another study, Liu et al. analysed data from 10,066 women 45 years of 
age or older who participated in the Women’s Health Study, and observed a median 
calcium intake of 857 mg/d and a median vitamin D intake of 266 IU/d. Interestingly, 
an inverse association between dietary calcium and metabolic syndrome was 
observed within each tertile of dietary vitamin D intake without significant interaction, 
suggesting that calcium intake was associated with a lower prevalence of the 
metabolic syndrome than vitamin D alone. However, the authors pointed out that the 
null findings for vitamin D intake might be attributed to an inadequate reflection of 
vitamin D intake on overall vitamin D status due to the lack of information on sun 
exposure. (159) 
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 Less attention has been given to adolescence.  Reis et al. conducted a cross-
sectional analysis of 3577 adolescents who participated in the 2001-2004 NHANES 
and concluded that low serum vitamin D in US adolescents is strongly associated 
with hypertension, hyperglycaemia, and metabolic syndrome, independent of 
adiposity(160), which is, to best of our knowledge the only study that evaluated the 
association between vitamin D status and the metabolic syndrome regarding the 
period of adolescence. 
    Even though the mechanisms are not fully comprehended, in the following it 
will be reviewed the current knowledge on the mechanisms by which vitamin D may 
influence some of the risk factors of the MetS. 
3.1. Vitamin D and obesity 
 
 The prevalence of obesity has increased in the past decades and it is 
presently the most common and costly nutritional problem. For example, in the 
United States, one-third of the population is affected by obesity, according to the 
National Health and Nutrition Examination Survey (NHANES)(161). Vitamin D 
deficiency is another increasingly prevalent public health concern in developed 
countries, and there is evidence that vitamin D metabolism, storage, and action 
influence and are influenced by adiposity(162).  
 Although the underlying explanations and direction of causality are unclear, 
observational studies have reported an increased risk in vitamin D deficiency in those 
who are obese. The probable explanation is that vitamin D is stored in the adipose 
tissue and, therefore, the association is that the larger storage capacity for vitamin D 
in obese individuals leads to lower circulating 25-hydroxyvitamin D [25(OH)D] 
concentrations, a marker for nutritional status(163).  
 As previously mentioned adipose tissue stores of vitamin D probably 
represent “non-specific” stores sequestered because of the hydrophobic nature of 
vitamin D, but the extent to which the processes of accumulation or mobilization are 
regulated by normal physiological mechanisms remains unknown. 
 Wortsman et al. concluded that in obese subjects, vitamin D was stored in 
adipose tissue and not released when needed(164). Blum et al. found that, in elderly 
subjects supplemented with 700 IU of vitamin D per day, for every additional 15 kg of 
weight above “normal” at baseline, the mean adjusted change in 25OHD level was 
approximately 10 nmol/L lower after 1 year of supplementation(165). The authors 
estimated that in order for subjects with body mass indexes (BMIs) above the normal 
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range to obtain an increase in serum 25OHD level similar to that of subjects with 
weight in the normal range, an additional 17 percent increase in vitamin D above the 
administered dose of 700 IU/day would be needed for every 10 kg increase in body 
weight above baseline in their study population. 
 Vimaleswaran et al. demonstrated that the association between BMI and 
lower 25(OH)D concentrations in Caucasian populations from North America and 
Europe can be seen across different age groups and in both men and women. They 
also showed that higher BMI leads to lower vitamin D status, highlighting the role of 
obesity as a possible causal risk factor for the development of vitamin D 
deficiency(163). 
 The implication of these studies is that vitamin D deposited in fat tissue is not 
readily available, and obese individuals may require larger than usual doses of 
vitamin D supplements to achieve a serum 25OHD level comparable to that of their 
normal weight counterparts(90). 
3.2. Vitamin D and blood pressure 
 
Growing evidence points to the existence of an association between vitamin 
D and blood pressure(166). In knockout mice was shown that the absence of vitamin D 
receptor activation leads to tonic upregulation of the renin-angiotensin system, with 
the development of hypertension and left ventricular hypertrophy(148, 167).  
 Indeed, evidence suggests that vitamin D may regulate blood pressure via 
regulating the renin-angiotensin system, which is a regulatory cascade that plays an 
essential role in the regulation of blood pressure, electrolyte and volume 
homeostasis. The main function of renin is to cleave angiotensin I (Ang), from 
angiotensinogen. Ang I is then converted to Ang II by the angiotensinogen-converting 
enzyme (ACE), which primarily resides in endothelial cells in blood vessels. In fact, 
Ang II is the central effector of the RAS. Through interacting with Ang II receptors in 
different tissues, including the brain, heart, kidney, adrenal glands and peripheral 
vasculature, Ang II exerts diverse physiological responses that influence the 
electrolyte and extracellular volume balance and blood pressure. Inappropriate 
stimulation of the RAS has been associated with hypertension. 
  In their work, Li and colleagues, concluded that, under normal physiological 
conditions, in addition to maintaining the blood calcium concentration, 1,25(OH)D 
antagonizes other renin-stimulating factors to maintain an appropriate renin level in 
the body. Therefore, the disruption of the Vitamin D signaling pathway should lead to 
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a deregulated stimulation of renin synthesis and consequently to an increase on 
blood pressure, whereas an increase in serum 1,25(OH)D levels should lead to renin 
suppression(148). 
 Data from NHANES III also showed an inverse association between blood 
pressure and vitamin D concentration. Martins et al verified that the adjusted 
prevalence of hypertension in adults was 30% higher in the lowest quartile compared 
to the highest quartile of serum 25(OH)D(155). 
 Forman et al. prospectively investigated the independent association between 
plasma 25(OH)D levels and risk of incident hypertension. Two prospective cohort 
studies that included 613 men from the Health Professionals’ Follow-Up Study and 
1198 women from the Nurses’ Health Study with measured 25(OH)D levels were 
followed for 4 to 8 years. After this follow-up, the risk of incident hypertension among 
those whose measured plasma 25(OH)D levels were <15ng/mL (compared with 
those whose levels were >30 ng/mL) was 6.13 in men and 2.67 in women(156).  
 Nevertheless, there have been studies that contradict this hypothesis as well. 
A large prospective study by Forman et al. in 2005 found no association between 
vitamin D intake from diet and supplements and the risk of incident hypertension(168). 
Likewise the randomized double-blind trial by Scragg et al. with a vitamin D 
supplementation at a single dose of 2.5mg in winter months did not show any 
significant decrease in blood pressure after 5 weeks when compared to placebo(169).  
 The conflict between the above-mentioned results suggests that the effect of 
vitamin D on blood pressure could be due to an indirect effect rather than a direct 
effect. In support of this hypothesis, some authors(170-172) identified a positive 
correlation between blood parathyroid hormone, which is usually high in 
hypovitaminosis D and high blood pressure, and this effect could be mediated 
through the action of parathyroid hormone on vascular smooth muscle cells of blood 
vessels. However, to clear this issue, using knockout mice Kong et al. verified the 
lack of involvement of parathyroid hormone in the suppression of blood pressure by 
vitamin D, showing that suppression of renin expression by 1,25-dihydroxyvitamin D 
in vivo is independent of parathyroid hormone and calcium(173). 
 
3.3. Vitamin D and glucose/insulin metabolism 
 
Interest in studying the relationship between vitamin D, glucose and insulin 
metabolism has been recently intensified due to the increase incidence of diabetes 
worldwide(2). 
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 Recent studies have shown a positive correlation between vitamin D 
deficiency and both diabetes(155) (174, 175) and insulin resistance(174, 176), suggesting that 
high vitamin D status offers protection from diabetes(177, 178). 
 Animal research supports the role for vitamin D in glucose and insulin 
metabolism. Studies have shown that vitamin D deficiency inhibits rat pancreatic 
insulin synthesis and secretion, which can be corrected by supplying the vitamin(179, 
180). In diabetic rats, 1,25-OH vitamin D3 injection increased insulin gene expression 
in liver and adipose tissue without affecting the insulin receptor affinity to insulin(181). 
Moreover, poor vitamin D status has been associated with β-cell dysfunction in both 
diabetic and non-diabetic subjects(182).  
 1,25(OH)2D, via VDR-mediated modulation of calbindin expression, appears 
to control intracellular calcium flux in the pancreatic islet cells, which in turn affects 
insulin release(183). 
 Observational studies also support these results. A meta-analysis of 
published work in this area revealed that vitamin D may play a role in the 
development of type-2 diabetes and in combination with adequate calcium intake 
vitamin D may favourably influence glucose metabolism(184). Reis et al., in their 
analysis of NHANES 2001–2004 data on adolescents, also showed an inverse 
relationship between 25(OH)D levels and plasma glucose concentrations(160). 
 
3.4. Vitamin D and dyslipidaemia 
 
The roles of vitamin D in dyslipidaemia have received much less attention 
from investigators compared to previously discussed risk factors(153). 
In a retrospective study, Guasch et al. observed 316 patients who had 
attended the obesity clinics in a Spanish hospital and categorized them by degree of 
adiposity, presence of MetS, and other comorbidities. They found that the prevalence 
of hyperparathyroidism increased from 12% in non-obese to 47.5% in morbidly 
obese individuals with BMI>50 kg/m2 and low plasma 25(OH)D and high PTH 
concentrations were associated with an increased risk of MetS and atherogenic 
dyslipidaemia, supporting the idea that a possible contribution of plasma 25(OH)D to 
the pathogenesis of hypertriglyceridemia and dyslipidaemia through inflammation(185). 
 Dyslipidaemia is a major contributing factor for atherosclerosis. Along with 
inflammation, it causes cardiovascular damage. Dyslipidaemia and a 
proinflammatory-prothrombotic state are characteristics of the metabolic syndrome. 
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There is compelling evidence that vitamin D status, and specifically 1,25-
dihydroxyvitamin D, can affect cytokine production and immunity. The hormonal form 
of vitamin D can inhibit the production of proinflammatory cytokines, including 
interleukin (IL)-1, IL-2, IL-6, tumor necrosis factor-α, and others, likely via the vitamin 
D receptor expressed in monocytes and activated T lymphocytes(186). Although it is 
well known that vitamin D plays a role in immunity, there is little evidence that vitamin 
D status is connected to the proinflammatory or prothrombotic components of the 
metabolic syndrome. Low circulating 25-hydroxyvitamin D levels have been noted in 
some patients with cardiovascular disease and dyslipidaemia, and hypovitaminosis D 
has been associated with increased total serum cholesterol concentration(187, 188). 
  Nonetheless, there is little evidence suggesting a likely mechanism by which 
vitamin D status could affect the development of dyslipidaemia(162). 
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4. The importance of adolescence 
 
Adolescence is one of the most exciting yet challenging periods in human 
development. This period, which comprises young people between the ages of 10 
and 19 years, involves enormous physiological, psychological and cognitive 
transformation, characterized by prompt growth and maturation during which a child 
becomes a young adult(189). 
 Early adolescence involves the rapid biological changes and their adjustment. 
Changes in cognitive and emotional functioning allow teens to become more 
independent as they mature. Peer influence and acceptance may become more 
important than family values, creating periods of conflict between teens and parents. 
Late adolescence is characterized by increased interest in future choices concerning 
adult life. It is a time when teenagers begin to emancipate and to consider what are 
their own ideals in order to start building their life goals(190).  
    Adolescents are often thought of as a healthy group. By the second decade 
of life they have survived the diseases of early childhood, have a low incidence of 
infections compared with younger children and the overwhelming health problems 
associated with ageing are still many years away. Nevertheless, the incidence of 
some diseases once considered to affect mainly the adult population, have been 
increasing in this age group(191).  
    Some of the diseases that affect the adulthood have their roots in 
adolescence. Even though cardiovascular disease events occur most frequently 
during or after the fifth decade of life, pathologic evidence suggests that precursors 
of cardiovascular disease originate in childhood(2, 34). Longitudinal studies have 
shown that risk factor levels in young adulthood track into and predict the occurrence 
of cardiovascular disease in adulthood(2). In fact, there is evidence that when 
exposed to risk factors, changes of atherosclerosis within blood vessels begin in the 
first decade of life as fatty streaks and plaques, which have been shown to regress 
through modification of behavioural risk factors(12). 
    Adolescence may, thus, be the key opportunity to intervene and prepare for a 
healthy adult life, preventing the onset of behaviours that will affect health and well 
being in the future, given the difficulty for people to change their behaviours in later 
life. Consequently, to know the relationship between vitamin D and cardiovascular 
risk factors in this age group, can help to better understand whether this 
micronutrient may be an added value for the ongoing battle against the development 
of cardiovascular disease in adulthood. 
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    Recently, IOM has increased the previous value for adequate intake for 
vitamin D (5µg) to 10 µg EAR for children 1 to 18 years of age for both genders(90), 
which highlights the increasing confidence of its beneficial role in public health. 
 A significant association between vitamin D and cardiovascular risk factors in 
youth may, therefore, suggest that the successful repletion of vitamin D has the 
potential to improve the cardiovascular risk profile during childhood and adolescence 
and to lower the risk of developing cardiovascular disease in adulthood.   
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Using the baseline information obtained after assembling the “Epidemiological Health 
Investigation of Teenagers in Porto” (EPITeen) cohort study, this research aimed to 
evaluate the vitamin D intake and its association to metabolic syndrome and its 
components in 13-year-old adolescents. 
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Vitamin D intake and metabolic syndrome among 13-year-old 
Portuguese adolescents 
 
 
Abstract 
 
Background: Growing evidence suggests a possible association between low 
vitamin D and increased cardiovascular risk. However, research regarding the period 
of adolescence is scarce. 
Objective: To evaluate the association of vitamin D intake with metabolic syndrome 
and its components in 13-year-old adolescents. 
Methods: We conducted a cross-sectional analysis of 1033 adolescents aged 13-
years-old, born in 1990 and enrolled at public and private schools in Porto, during the 
2003/2004 school year. Self-administered questionnaires were applied and vitamin D 
intake was assessed by a food frequency questionnaire. Anthropometric 
assessment, blood pressure measurement and fasting blood sample collection were 
performed. Metabolic syndrome components were defined according to the National 
Cholesterol Education Program Adult Treatment Panel III definition modified for age. 
Logistic regression was performed in order to estimate the association between 
vitamin D intake and metabolic syndrome components.  
Results:  Median (P25-P75) vitamin D intake was 4.11 (2.88-5.60)  µg; it was higher 
among adolescents who reported the use of vitamin supplements and lower in those 
classified as obese or abdominally obese. Metabolic syndrome prevalence was 
13.2%. The adjusted odds ratio (95% confidence interval) increased with the 
decrease of vitamin D intake until 1.22 (0.84-1.78) for low HDL cholesterol and 1.78 
(1.00-3.17) for high BMI. 
Conclusions: Notwithstanding the extremely low vitamin D intake, an inverse 
relation with high BMI and low HDL cholesterol was observed, though without 
statistical significance. No trend was found for metabolic syndrome. 
 
Key words: Vitamin D, metabolic syndrome, adolescents. 
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Introduction 
 
 
Cardiovascular disease (CVD) remain the leading cause of death and disability 
worldwide(1). Although the events occur most frequently during or after the fifth 
decade of life, longitudinal studies have shown that risk factors persist from 
childhood into adulthood in a large percentage of cases (25-60%)(2, 3) and predict the 
occurrence of CVD in later life(4). 
Besides the contribution to the rise in obesity, the “obesogenic” environment that has 
been installed in society during the last decades has also contributed to the increase 
in metabolic/physiologic changes (5): raised blood pressure (hypertension); 
overweight/obesity; impaired glucose and raised blood lipids (dyslipidaemia). The 
clustering of these risk factors, which is associated with insulin resistance and co-
occur more often than it might be expected by chance, is called the Metabolic 
Syndrome (MetS)(6).  
Vitamin D, first identified in the 20th century and known as “the sunshine vitamin” 
due to its particularity of a nutrient that can be synthesized by the human body 
through the action of sunlight, is now recognized as a pro-hormone. For decades, a 
great deal of attention has been justifiably placed on understanding the 
consequences of vitamin D deficiency on bone health(7-9). However, recent studies 
have broadened the horizon, suggesting that vitamin D levels may play an important 
role in cardiovascular disease(10-13).  
Vitamin D biological actions involve regulation of gene expression at the 
transcriptional level, and are mediated through binding to a vitamin D receptor 
(VDR), located primarily in the nuclei of target cells. The acknowledgement that VDR 
is found fairly present throughout the body in tissues not involved with calcium and 
phosphate homeostasis, implies that the presence of VDRs in these tissues may play 
a more general role than it was previously thought(14, 15).  
The mechanisms by which vitamin D may be linked to metabolic syndrome involve 
the blunting effect of advanced glycation end products on endothelial cells, which 
contribute to the increased arterial stiffness and endothelial dysfunction observed in 
individuals deficient in vitamin D. Additionally, vitamin D may also exert protective 
effects on the vessel walls by inhibition of macrophage to foam cell formation and via 
its anti-inflammatory effects. Lastly, vitamin D sufficiency has been associated with 
downregulation of the renin-angiotensin-aldosterone system(16).   
Despite the emerging evidence of an association between low circulating 
concentrations of vitamin D and the prevalence of metabolic syndrome(17, 18), 
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epidemiologic evidence regarding vitamin D intake to the metabolic syndrome is 
limited. Notwithstanding, the Institute of Medicine (IOM) has increased the previous 
value for adequate intake for vitamin D (5µg) to 10 µg EAR(19), highlighting the 
increasing confidence of its beneficial role in public health. 
Once the metabolic syndrome and its components often begin to be established 
throughout adolescence(20), this is a period when a dietary intervention to prevent the 
occurrence of disease and its consequences may conduct to greater benefits(21).  
The present study aimed at examining the association of vitamin D intake with 
metabolic syndrome and its components in 13-year-old adolescents. 
 
 
Methods 
 
Eligible participants were urban adolescents, members of the Epidemiological Health 
Investigation of Teenagers in Porto (EPITeen). As reported elsewhere(22), we 
evaluated adolescents born in 1990, who were enrolled at public and private schools 
in Porto, Portugal, during the 2003/2004 school year. Data were collected using two 
self-administered questionnaires, one fulfilled at home and another at school. The 
home questionnaire inquired about demographic, social, behavioural and clinical 
characteristics of the children and the family. A physical examination was performed 
at school, by a team of experienced nurses, nutritionists and physicians.  During the 
research team visit, children answered an additional questionnaire comprising further 
information on physical activity, smoking and alcohol intake. 
 
 
Assessment of vitamin D intake 
 
As part of the home questionnaire, food intake was recorded using a food frequency 
questionnaire (FFQ) regarding the previous 12 months, fulfilled by the adolescents at 
home with the help of their parents or legal guardians. The FFQ was designed 
according to Willett and colleagues(23) and adapted for the Portuguese population, 
according to dietary data available for our country, namely the Portuguese food 
balance sheets and other specific studies(24). Foods with similar nutrient composition 
were grouped together as a single food item. The questionnaire was validated for the 
adult population by comparison with four 7 daily food records (each one in a different 
season of the year)(24). The FFQ was then adapted for adolescents by including 
foods more frequently eaten by this age group. The adolescents’ version comprised 
ninety-one food items or beverage categories and a frequency section with nine 
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possible responses ranging from never to six or more times daily. It also included an 
open-ended section for foods not listed in the questionnaire, but eaten at least once 
weekly. 
Food intake data were obtained by multiplying the frequency of consumption of each 
food item by the nutrient content of the specified portion size. Seasonal variation of 
food consumption was also considered according to participants’ replies. To estimate 
nutrient intake from the evaluated food intake, we used the software Food Processor 
Plus® (ESHA Research, Salem, OR, USA) based on values from the US Department 
of Agriculture. Values for typical Portuguese foods were added, based on the 
Portuguese tables of food composition, typical recipes and data from previous 
studies(25). The nutrient content of food items which are usually eaten cooked was 
estimated by considering cooking and processing. 
 
Assessment of other covariates 
 
Questionnaires 
 
Adolescent smoking status was self-reported and participants were classified as 
never or ever smokers, this last category comprising those that just experienced a 
puff up to currently smoking adolescents. 
Drinking behaviour was assessed through the question “Have you ever drunk an 
alcoholic beverage?”. Adolescents were classified as “never drinker” or “ever 
drinker”, this last category comprising those who had only experimented to those 
who drink at least once per month. 
Physical exercise was assessed using a questionnaire covering various daily 
activities. Sport activities were considered as regular scheduled sport activities 
outside school.  
Leisure time activities were classified according to a multiple-choice question 
proposing four subjective intensity categories (mainly sitting, mainly standing, active 
or very active). Average weekend time spent watching TV, playing computer and 
reading was recorded and added to compute total time spent in sedentary activities. 
Parental education level was measured as the number of successfully completed 
years of formal schooling and adolescents were classified according to the parent 
with the higher education level. 
Family history of disease comprised information on diabetes, hypertension and 
dyslipidaemia. It was asked if the disease had ever been diagnosed, separately for 
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each disease and for each parent. The possible answers were "yes", "no" and "do 
not know".  
 
Anthropometrics 
 
Weight and height were obtained with the subject in light indoor clothes and no 
shoes. Weight was measured in kilograms, to the nearest tenth, using a digital scale 
and height was measured in centimetres, to the nearest tenth, using a portable 
stadiometer. Adolescents were classified according to the age- and sex-specific BMI 
based on the Center for Disease Control and Prevention’s 2000 BMI-for-age growth 
charts for the United States(26). Based on this data we classified those above the 95th 
percentile as obese and those between the 85th and 95th percentiles as overweight. 
Body fat percentage was estimated by bioelectrical impedance, using Tanita® (Tanita 
TBF-300, Tanita Corporation of America, Inc., Illinois, USA).  
Waist circumference was measured to the nearest centimetre, midway between the 
lower limit of the rib cage and the iliac crest, with the subject standing, using a 
flexible and non-distensible tape and avoiding exertion of pressure on the tissues. 
 
Blood pressure 
 
Blood pressure was measured with a mercury sphygmomanometer using the 
auscultatory method, following the recommendations of the American Academy of 
Paediatrics(27). Classification was based on the mean of two readings taken on a 
single occasion, separated by at least 10 minutes’ rest, with a third reading being ta- 
ken if the difference between the first two was over 5 mmHg. High blood pressure 
was defined according to the quantitative criteria of the American Academy of 
Paediatrics(27):  systolic or diastolic blood pressure above the 90th percentile for age, 
gender, and height.  
 
Laboratory measures 
 
A venous blood sample was drawn after a 12-hour overnight fast. All the samples 
were analysed at the central laboratory of the university hospital. Serum glucose, 
cholesterol and triglycerides were determined using automatic standard routine 
enzymatic methods. High-density lipoprotein (HDL)-cholesterol was determined after 
precipitation of apolipoprotein B-containing lipoproteins. Serum insulin was measured 
using a 125I-labelled insulin radioimmunoassay method, and insulin resistance was 
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estimated according to the homeostatic model assessment (HOMA), as the product 
of fasting glucose (mmol/L) and insulin (µUI/mL) divided by a constant 22.5(28). 
 
 
Metabolic syndrome 
 
For this analysis metabolic syndrome components were defined according to the 
National Cholesterol Education Program Adult Treatment Panel III definition modified 
for age(29).  
Components were defined as follows: (1) waist circumference ≥ 75th percentile(30) for 
age and gender; (2) HDL cholesterol ≤ 50 mg/dL; (3) triglycerides ≥ 110 mg/dL; (4) 
systolic or diastolic blood pressure ≥ 90th percentile for age, gender, and height(31); 
and (5) fasting glucose ≥ 100 mg/dL. The presence of the metabolic syndrome 
phenotype was defined as having 3 or more of these 5 characteristics(29). 
 
Participants 
 
Two thousand seven hundred and eighty-six eligible participants were identified. 
Among them, forty-four (1.6 %) could not be reached, 583 (20.9 %) were refusals (no 
signed informed consent form was returned) and 2159 agreed to participate and 
provided information at least for part of the planned assessment, resulting in an 
overall participation rate of 77.5 %, similar in public (77.7 %) and private (77.0 %) 
schools (p=0.709). 
Of the 2159 participants, 247 did not return the home questionnaire and 297 did not 
fill in the FFQ or were excluded because no information was provided on more than 
10 % of food items. A further ninety-three participants were not considered for the 
current analysis because their total energy intake was more than 3 times the 
interquartile range or their intake of fruit or vegetables was more than 1.5 times the 
interquartile range. Additionally, 72 participants did not perform the anthropometric 
measurements; other 409 did not undergo blood collection, as well as 8 participants 
did not perform blood pressure measurement. Thus, the analysis was based on the 
information of 1033 participants. 
 
Statistical Analysis 
 
The distribution of quantitative variables was checked using the Kolmogorov-Smirnov 
test. Proportions were compared using the chi-square test or Fisher’s exact test, 
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whenever appropriate, and quantitative variables using the Kruskal-Wallis or Mann-
Whitney test, the results being presented as medians (percentile 25 - percentile 75).  
Crude and adjusted means and 95% confidence intervals (95% CI) of selected 
anthropometric and metabolic characteristics were calculated according to quartiles 
of vitamin D intake, using liner regression adjusted for gender, BMI, physical activity 
and trimester of evaluation.  
Logistic regression models were used to estimate odds ratio and 95% CIs for 
metabolic syndrome and its components according to quartiles of vitamin D intake. 
Models were adjusted for gender, BMI, physical activity and trimester of evaluation. 
In all tests, statistical significance was considered with an alpha critical value of 0.05. 
Statistical analyses were performed using the Statistical Package for the Social 
Sciences (IBM® SPSS® Statistics), version 21.0. 
 
 
 
Ethical Considerations 
 
The Ethics Committee of Hospital S. João approved the study and written consent 
was obtained from both legal guardians and adolescents. In accordance to the study 
protocol, the results of the assessments were provided as individual reports 
addressed personally to the adolescents’ legal guardians, with an explicit 
recommendation that they should be communicated to the family physician. This 
indication was given in all cases, irrespective of the results. 
 
 
Results 
 
In this analysis we included 1033 participants and their characteristics were 
compared to those from excluded adolescents (table 1). Both groups were similar, 
except for the type of school, with participants not included being mostly from public 
schools, and with less educated parents, presenting higher activity spent in leisure 
time outside school and less alcohol consumption.   
Table 2 presents the description of metabolic syndrome and its components in our 
sample. The most prevalent component was low HDL cholesterol, with 53.3% of 
participants showing values equal to or below 50 mg/dL. In contrast, the component 
with the lowest prevalence was high glucose levels (0.6%). We found a prevalence of 
metabolic syndrome of 13.2%. 
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Table 3 displays the median of vitamin D intake according to demographic and 
clinical characteristics of the participants. We observed a very low vitamin D intake of 
4.11 (2.88-5.60) µg among participants. The median of vitamin D intake was higher 
among adolescents who reported the use of vitamin supplements and, although not 
statistically significant, there was a trend toward a lower mean vitamin D intake in 
girls and in those who practice less physical activity. The intake was lower in those 
defined as obese or abdominally obese, as well as in those who had low HDL 
cholesterol. No differences were observed in vitamin D intake by blood pressure, 
level of glucose, level of triglycerides and the metabolic syndrome. 
The crude mean (95% CI) of selected anthropometric and metabolic characteristics 
according to quartiles of vitamin D intake is shown in table 4. Significant trends for 
lower BMI and waist circumference were observed in adolescents with higher vitamin 
D levels, although the latter not showing statistical significance. No association was 
observed between vitamin D intake and the other components evaluated. After 
adjusting for gender, BMI physical activity, and trimester of evaluation no significant 
difference was observed (table5).  
The multivariable-adjusted associations between vitamin D intake and metabolic 
syndrome and their components are shown in Table 6. Even though no significant 
association was observed, the adjusted odds ratios for BMI and HDL cholesterol 
increased with the decreasing quartile of vitamin D intake. It was not computed the 
Odds Ratio regarding elevated fasting glucose, due to the very low prevalence of this 
component. 
 
 
Discussion 
 
In this sample of 13-year-old adolescents we found a very low vitamin D intake from 
diet. The median of vitamin D intake was 4.11 (2.88-5.60) µg, far below the 10 µg 
recommended by IOM, reinforcing the descriptions of the worldwide high prevalence 
of vitamin D deficiency (32, 33), also observed in adolescents from other European 
countries (34).  
Despite the low intake, a mild increase of prevalence of obesity and central obesity 
was observed with the decreasing quartile of vitamin D, however the effect was not 
statistically significant. Few studies have addressed the effect of dietary vitamin D on 
cardiovascular risk factors (13, 35, 36), and to best of our knowledge none has 
addressed the period of adolescence.  
Once the human body through the action of sunlight can synthesize vitamin D and 
serum concentrations were not determined in the current analysis, we cannot fully 
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confirm this hypothesis. However, although 25(OH)D concentration in the human 
body is the biologically internal dose of the total exposure of vitamin D, this work 
strengthens the need to take into consideration the part of vitamin D that comes from 
diet and supplementation, since in a country plentiful in sun, it is observed an inverse 
relation between some of the most prevalent components of the metabolic syndrome 
and vitamin D intake.  
Trends for a lower BMI were verified in adolescents with higher vitamin D levels. 
Although it has often been suggested the sequestration within adipose tissue as an 
explanation for the lower levels of vitamin D in subjects with a higher BMI (37, 38), our 
results indicate that the lower vitamin D intake by these individuals should also be 
considered as a possible explanation. 
Although there is increasing evidence that vitamin D may be a negative endocrine 
regulator of the renin-angiotensin system, through the inhibition of the renin gene 
expression by the activated metabolite of 25(OH)D, 1,25-dihydroxyvitamin D 
(1,25[OH]2D), in the current study, we observed no independent cross-sectional 
association among dietary vitamin D, systolic and diastolic blood pressure, and 
hypertension. These findings are in agreement with a large prospective study of Forman 
et al. in 2005 that found no association between vitamin D intake from diet and 
supplements and the risk of incident hypertension(39). No relation was also observed 
between triglycerides across increasing quartiles of vitamin D intake, which is 
accordant with Fung et al., who evaluated associations of dietary and supplemental 
vitamin D intake with the 20-y incidence of metabolic syndrome from 4727 black and 
white young men and women from the Coronary Artery Risk Development in Young 
Adults study (CARDIA) and found no relation between blood pressure and 
triglycerides across increasing quintiles of vitamin D(13).  
No differences were observed between quartiles of vitamin D and glucose, insulin 
and, consequently, neither in HOMA. A possible reason for this observation is that 
the majority of participants are considered healthy and the measures to assess 
insulin resistance may not be the most appropriate. The gold standard assessment of 
insulin resistance requires an invasive and impractical application in children and 
adolescents (40), therefore, simple tools were considered valid, as fasting glucose, 
insulin levels and the HOMA index(41-43). 
Despite the extremely low intake of vitamin D, it was observed an inverse relation 
with high BMI and low HDL cholesterol. Although some studies found an inverse 
association between vitamin D and dyslipidaemia, is not yet clarified the mechanism 
that can explain this observation (44). 
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This investigation had strengths and limitations. The FFQ has some restraints in 
assessing dietary intake, which include the use of a predetermined food list that 
might not be representative of foods eaten by a specific population (23). However, we 
believe that this possible bias had a very low effect, because this FFQ was validated 
for the adult population (25) and some foods or food groups eaten more frequently by 
the adolescent age group were included in the questionnaire. Likewise, adolescents 
were encouraged to list foods eaten at least once weekly not enumerated in the FFQ, 
in an open section. The reliance on participants’ recall and the requirement of 
motivated participants, especially in self-administered questionnaires is another 
limitation of the FFQ(23). Although it was self-administered, adolescents were given 
oral instructions on filling it in and written instructions were also sent home along with 
the questionnaire. Despite having completed it with the help of their parents or legal 
guardians, which may have improved the quality of information, the extent to which 
parents might have an influence on overestimating healthy foods (according to what 
is socially acceptable) and on underestimating unhealthy foods is unknown.  
We chose not to evaluate data regarding the portion size of the food intake. We 
expect this option to not have an impact on our results since previous studies 
suggest that to record information on portion size does not substantially improve the 
assessment of dietary intake(23), which may be more relevant in adolescents who 
may have difficulty in estimating the portions and frequently ignore these questions 
when questionnaires are self-administered(45). 
A potentially important source of vitamin D originates from sun exposure, which was 
not measured in this study. Since sunlight exposure substantially affects vitamin D 
levels, this might represent a limitation, as data on sun exposure were not available 
in EPITeen datasets. Nonetheless, the analysis was conducted over the year and 
adjusted for trimester of evaluation to take into account seasonal variation. 
Information was collected on the type of supplement taken, allowing to understand 
whether participants were taking vitamin D supplementation, being confirmed the 
high dose of vitamin D for the most part, whereas it was not possible to confirm the 
composition for a minority. Thus, it was considered whether the participant took or 
did not take the supplement, assuming that those who took were taking high doses of 
vitamin D. Once this information did not change the results, the variable was not 
considered in the final models. 
Notwithstanding the above limitations, this study is one of the few that has assessed 
vitamin D intake in adolescents and its relation with the metabolic syndrome. 
Moreover, the dataset employed was from a population-based sample, which may 
enhance generalizability. However, because data are cross-sectional, the causative 
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nature of associations cannot be determined. Yet, it is no expected that participants 
have altered their intake in consequence of the components evaluated. Therefore, 
we can assume that the relation verified is not the result of inverse causality. Future 
studies with a long-term longitudinal design are warranted to better understand the 
mechanisms that can explain the relation observed. 
  
 
Conclusion 
 
In summary, despite the extremely low vitamin D intake, an inverse relation with high 
BMI and low HDL cholesterol was observed. Even with an intake lower than 
recommended, there is a decreasing odds of this components with the increasing 
intake of vitamin D, though without statistical significance. Additional research is 
necessary to determine the long-term consequences of vitamin D deficiency, 
including whether low vitamin D levels during childhood significantly predict the 
occurrence of cardiovascular disease in adulthood. 
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Table 1. Description and comparison of participants’ characteristics included and excluded in the 
analysis: 13-year-old adolescents, Porto, Portugal, 2003/2004 school year.  
 Excluded (n=1126) Included (n=1033)  
Characteristic n % n  % p 
Sex       
Girls 562 49.9 554 53.6 0.084 
Boys 564 50.1 479 46.4  
School      
Public 896 79.6 754 73.0 <0.001 
Private 230 20.4 279 27.0  
Parental education (years)      
0-6 327 31.4 240 23.5 0.001 
7-9 203 19.5 218 21.3  
10-12 255 24.5 281 27.5  
>12 256 24.6 284 27.8  
Missing (n) 85  10   
Leisure-time physical activity      
Mainly sitting 228 26.6 281 27.2 0.014 
Mainly standing  161 18.8 234 22.7  
Active 224 26.1 306 29.6  
Very active 176 20.5 164 15.9  
Missing (n) 68  48   
Fruit consumption (portions/week)      
<1/day 397 35.3 457 44.2 0.185 
≥1 and < 2/day 265 23.5 370 35.8  
≥2/day 147 13.1 188 18.2  
Missing 317  18   
Vitamin supplementation       
No 638 72.7 779 75.4 0.483 
Yes 182 20.8 205  19.8  
Missing 306  49   
Smoking      
No 757 74.8 769 75.2 0.796 
Yes 227 22.4 237 23.2  
Missing 142   27  
Alcohol intake      
No 484 43.0 441 42.7 0.024 
Yes 506 44.9 565 54.7  
Missing 136  27   
Family history of disease       
Diabetes       
No 816  72.5 895 86.6 0.120 
Yes 79 7.0 76 7.4  
Do not know 33 2.9 21 2.0  
Missing 198  41   
Cholesterol      
No 568 50.4 604 58.5 0.004 
Yes 318 28.2 374 36.2  
Do not know 62 5.5 35 3.4  
Missing 178  20   
Hypertension      
No 678 60.2 731 70.8 0.101 
Yes 235 20.9 261 25.3  
Do not know 36 3.2 22 2.1  
Missing 177  19   
Anthropometrics      
BMI <85th  767 76.3  758 73.4 0.306 
BMI ≥85th and <95th  149 14.8 170 16.5  
BMI ≥95th percentile 88 8.9 105 10.2  
Missing 121  0   
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Table 2. Characteristics of the participants according to metabolic syndrome and its components.  
 
Characteristic Median (P25-P75) or % 
Waist circumference ≥75th percentile 26.0 
Blood pressure  
Systolic blood pressure, mm Hg 112.0 (105.0-1220.0) 
Diastolic blood pressure, mm Hg 68.0 (62.0-73.0) 
High blood pressurea 33.6 
Diabetes related measures  
Fasting glucose, mg/dL 85.0 (80.0-91.0) 
Fasting glucose ≥ 110mg/dL 0.6 
Lipids  
HDL cholesterol ≤ 50 mg/dL 53.3 
HDL cholesterol, mg/dL 48.0 (42.0-56.0) 
Triglycerides ≥ 100 mg/dL 11.5 
Triglycerides, mg/dL 58.0 (46.0-78.0) 
Metabolic syndromeb 13.2 
a Data are defined as systolic or diastolic blood pressure ≥ 90th percentile for age, gender and 
height(27) 
b Data are defined according to the method of de Ferranti et al(29) 
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Table 3.  Vitamin D intake (µg) according to participants’ characteristics. 
Variable n 
 Vit D intake  
Median (P25-P75), 
µg 
P 
Overall 1033 4.11 (2.88-5.60)  
Sex    
Girls 554 4.02 (2.80-5.43) 0.050 
Boys 479 4.26 (2.99-5.72)  
Vitamin Supplementation    
No 779 4.02 (2.86-5.48) 0.014 
Yes 205 4.42 (3.02-6.12)  
Parental education (years)    
0-6  4.13 (2.98-5.67) 0.462 
7-9  4.30 (2.82-5.86)  
10-12  4.27 (2.30-5.35)  
>12  3.85 (2.76-5.47)  
Physical activity    
Mainly sitting 281 3.94 (2.71-5.55) 0.062 
Mainly standing 234 3.97 (2.78-5.55)  
Active 306 4.15 (3.00-5.44)  
Very active 164 4.47 (3.01-6.14)  
BMI ≥95th percentilea    
No 928 4.16 (2,96-5.63) 0,005 
Yes 105 3.73 (2.43-5.08)  
Waist circumference ≥75th percentilea    
No 764 4.16 (2.95-5.68) 0,005 
Yes 269 3.87 (2.72-5.06)  
High blood pressureb    
No 686 4.13 (2.91-5.94) 0,763 
Yes 347 4.06 (2.83-5.63)  
Fasting glucose ≥ 110mg/dL    
No 1027 4.11 (2.89-5.60) 0,690 
Yes 6 3.80 (2.65-5.28)  
HDL cholesterol ≤ 50 mg/dL    
No 482 4.28 (3.05-5.63) 0,004 
Yes 551 3.90 (2.75-5.50)  
Triglycerides ≥ 100mg/dL    
No 914 4.07 (2.89-5.53) 0,218 
Yes 119 4.37 (2.84-6.01)  
Metabolic Syndromec    
No 897 4.15 (2.94-5.58) 0,209 
Yes 136 3.85 (2.65-5.67)  
a Data are according to age and gender. 
b Defined as systolic or diastolic blood pressure above the 90th percentile for age, gender, and height(27)  
c Defined according to the definition of de Ferranti et al.(29) 
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Table 4. Mean (95% CI) of selected anthropometric and metabolic characteristics according to quartiles of vitamin D 
intake.  
 
Quartiles of Vitamin D intake, µg 
Variable  I (<2.88) II (2.88-4.10) III (4.11-5.60) IV (>5.60) P 
Blood Pressure, mm Hg      
Systolic  113.3 (111.9-114.8) 113.8 (112.4-115.2) 112.1 (110.8-113.4) 112.6 (111.2-114.0) 0,301 
Diastolic  67.6 (66.6-68.6) 67.6 (66.6-68.5) 68.0 (66.9-69.1) 68.3 (67.4-69.3) 0,680 
Lipids, mg/dL      
Total cholesterol 166.7 (162.8-170.6) 165.5 (161.7-169.3) 166.9 (163.0-170.8) 165.7 (161.9-169.4) 0.940 
HDL cholesterol  48.1 (46.7-49.5) 48.9 (47.6-50.2) 50.6 (49.2-52.0) 49.1 (47.6-50.6) 0.088 
LDL cholesterol 105.3 (102.1- 108.5) 103.7 (100.6- 106.7) 103.6 (100.6- 106.6) 103.4 (100.4- 106.4) 0.827 
Triglycerides 66.5 (63.0- 70.0) 64.7 (60.9- 68.5) 63.4 (60.0- 66.9) 65.9 (62.4- 69.4) 0.639 
Diabetes-related measures      
Fasting glucose, mg/dL 84.2 (83.0-85.3) 84.6 (83.5-85.8) 85.3 (84.1-86.5) 86.1 (84.9-87.3) 0.113 
Fasting insulin, µU/mL 7.9 (7.2-8.7) 8.1 (7.3-9.0) 8.1 (7.4-8.8) 7.7 (7.0-8.4) 0.867 
Homa -IR 1.7 (1.5-1.8) 1.7 (1.5-1.9) 1.7(1.6-1.9) 1.7 (1.5-1.8) 0.926 
Anthropometrics       
BMI 21.6 (21.1-22.1) 21.2 (20.8-21.6) 20.9 (20.5-21.3) 20.7 (20.3-21.1) 0.023 
Waist circumference  73.5 (72.5-74.6) 72.9 (71.8-74.0) 72.8 (71.7-73.9) 71.6 (70.7-72.6) 0.088 
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Table 5. Adjusted mean (95%CI) of selected anthropometric and metabolic characteristics according to quartiles of 
vitamin D intake among participants. 
Quartiles of Vitamin D intake, µg 
Variable  I (<2.88) II (2.88-4.10) III (4.11-5.60) IV (>5.60) P 
Blood Pressure, mm Hg      
   Systolica  117.0 (115.4-118.6) 117.7 (116.1-119.3) 116.1 (114.4-117.7) 116.6 (115.0-118.2) 0.380 
Diastolica  70.1 (68.9-71.3) 70.2 (69.0-71.4) 70.9 (69.7-72.1) 71.1 (69.9-72.3) 0.411 
Lipids, mg/dL      
Total cholesterola 167.1 (162.4-171.7) 165.7 (161.0-170.4) 166.4 (161.7-171.2) 165.6 (161.0-171.4) 0.945 
HDL cholesterola 47.0 (45.3-48.6) 47.2 (45.5-48.8) 48.2 (46.5-49.8) 46.7 (45.1-48.3) 0.435 
LDL cholesterola 105.8 (102.0- 116.2) 104.5 (100.7-108.3) 104.2 (100.4- 108.0) 104.5 (100.8-108.2) 0.906 
Triglyceridesa 71.3 (67.5-76.0) 70.1 (65.8-74.4) 70.2 (65.9-74.5) 72.0 (67.8-76.2) 0.822 
Diabetes-related measures      
Fasting glucose, mg/dLa 84.8 (83.4-86.2) 85.6 (84.2-87.1) 86.4 (84.9-87.8) 86.7 (85.2-88.1) 0.139 
Fasting insulin, µU/mLa 9.6 (8.8-10.5) 10.2 (9.3-11.1) 10.4 (9.5-11.3) 9.8 (9.0-10.7) 0.529 
Homa -IRa 2.0 (1.8-2.2) 2.2 (2.0-2.4) 2.2(2.0-2.4) 2.1 (1.9-2.3) 0.383 
Anthropometrics       
BMIb 21.2 (20.7-21.7) 20.9 (20.5-21.4) 20.7 (20.2-21.2) 20.5 (20.1-21.0) 0.142 
Waist circumference a 79.0 (78.3-79.8) 79.6 (78.8-80.3) 79.6 (78.8-80.4) 78.7 (78.0-79.5) 0.180 
a Adjusted for gender, BMI, physical activity and trimester of evaluation. 
b Adjusted for gender, physical activity and trimester of evaluation. 
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Table 6. Adjusted odds ratios and 95% CIs of metabolic syndrome and its components according to vitamin D intake 
among participants.  
 
Variable I (<2.88) II (2.88-4.10) III (4.11-5.60) IV (>5.60) 
BMI  ≥ 95th percentilea     
Prevalence, % 15.2 8.9 8.1 8.5 
Adjusted OR 
(95% CI) 
1.78 (1.00-3.17) 1.00 (0.53-1.88) 0.93 (0.49-1.78) 1.00 (reference) 
Waist circumference ≥ 75th 
percentileb 
    
Prevalence, % 30.0 27.5 25.5 21.2 
Adjusted OR 
(95% CI)b 
1.01 (0.50-2.05) 1.29 (0.65-2.57) 1.27 (0.64-2.50) 1.00 (reference) 
High blood pressurec     
Prevalence, % 35.0 32.9 32.8 33.6 
Adjusted OR 
(95% CI)b 
0.99 (0.67-1.49) 0.95 (0.64-1.41) 0.98 (0.66-1.45) 1.00 (reference) 
Fasting glucose ≥ 
110mg/dL† 
    
Prevalence, % 0.8 0.4 0.8 0.4 
HDL cholesterol ≤ 50 
mg/dL 
    
Prevalence, % 59.1 55.0 47.9 51.4 
Adjusted OR 
(95% CI)b 
1.22 (0.84-1.78) 1.07 (0.76-1.58) 0.86 (0.60-1.25) 1.00 (reference) 
Triglycerides ≥ 110 mg/dL     
Prevalence, % 12.1 8.9 10.4 14,7 
Adjusted OR 
(95% CI)b 
0.76 (0.44-1.32) 0.50 (0.28-0.90) 0.70 (0.40-1.22) 1.00 (reference) 
Metabolic syndromed     
Prevalence, % 16.0 12.4 10.8 13.5 
Adjusted OR 
(95% CI)b 
0.77 (0.41-1.46) 0.64 (0.34-1.24) 0.58 (0.29-1.15) 1.00 (reference) 
a Adjusted for physical activity and trimester of evaluation;  BMI classified according to age and gender(29) 
b Adjusted for gender, physical activity, BMI and trimester of evaluation. 
c Defined as systolic or diastolic blood pressure above the 90th percentile for age, gender, and height(27).  
d Defined according to the definition of de Ferranti et al(29). 
† Few cases to measure the association  
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This research, based on a population-based sample of Portuguese adolescents, 
allowed the following conclusions: 
 
 
 A very low intake of vitamin D was observed, with a median (percentile 25- 
percentile 75) of 4.11 (2.88-5.60) µg, far below the 10 µg recommended by IOM, 
supporting the possibility of having a high prevalence of vitamin D deficiency. 
  
 A highly prevalence of metabolic syndrome was found (13.2%). Regarding its 
components, the most prevalent were high blood pressure and dyslipidaemia. 
Notwithstanding the extremely low vitamin D intake, an inverse relation with high BMI 
and low HDL cholesterol was observed, though without statistical significance. No 
trend was found for metabolic syndrome. 
 
 These results reinforce the need for preventive measures in order to revert, or 
minimize, the risk of cardiovascular disease later in life. One of these measures may 
be to improve the vitamin D intake, which, beyond the cardiovascular protective 
effect, also could promote other health benefits. 
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